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ABSRACT 
Epidemiological studies indicated that vitamin A status is associated with plasma 
fibrinogen levels. It has been shown that Africans have high plasma fibrinogen levels 
compared to Europeans, probably contributing to their high risk for stroke. In this study 
the hypothesis that increased intakes of vitamin A will lower plasma fibrinogen levels, 
has been examined. The study formed part of a clinical intervention trial under controlled 
conditions to examine the effects of vitamin A fortified sugar on plasma fibrinogen of 
African females aged \3-25 years. 
The methodology included questionnaires determining demographic profile, food 
consumption patterns and compliance to fortified sugar consumption. Measurements 
included anthropometric measurements and double baseline biochemical measurements 
on 95 subjects in the randomly selected sample population. The sample population was 
randomly divided into an experimental (n=46) group consuming fortified sugar (80 IU 
vitamin A per gram sugar), and a control group (11=49) consuming non-fortified sugar. 
Measurements were repeated after 4, 8 and 12 weeks of sugar consumption. Plasma 
fibrinogen levels were determined by the Dade Behring - Multifibren® U method. The 
method is a modification of the Clauss method. 
The baseline measurements of plasma fibrinogen showed that 5.1 % of respondents had a 
fibrinogen level of < 2.71 gil, 83.8% a fibrinogen level 2.72 - 3.30 gil and 11.1 % of 
respondents had a fibrinogen level> 3.30gll. 
Baseline measurements of serum vitamin A indicated that 12% of respondents had a level 
of<30 flgldl, 33.7 % a level of30-40flgldl, 38.6% a level of40-50flgldl and 15.7% of the 
respondents had a serum vitamin A level of>50flgldl. 
During the experimental period, the subjects consumed approximately 60g sugar per day, 
providing an additional 4800 IU or 1446 flg RE vitamin A per day to the experimental 
group. 
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The results indicated that mean plasma fibrinogen levels of the experimental subjects 
were significantly lower than the baseline results (2.8t gIL) after 4 weeks (2.64 gIL) and 
8 weeks (2 .65 giL). However, levels increased and returned to baseline levels at week 12 
(2 .84 giL). The experimental subjects showed an increase in body weight at week 12, and 
it is speculated that this increase could have been responsible for the increase in plasma 
fibrinogen. 
In conclusion the study confirmed that by the intake of fortified sugar providing 
additional vitamin A in the diet of these African women, the plasma fibrinogen levels 
were significantly decreased at 4 and 8 weeks. It is further recommended that the 
influence of vitamin A on fibrinogen should be examined in subjects with raised 
fibrinogen and decreased vitamin A levels. 
This work has been presented ...... .. ....... .. .. see Annexure 12. 
Key words: Fibrinogen, vitamin A fortification 
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OPSOMMING 
Epidemiologiese studies toon aan dat vitamien A status geassosieer word met 
plasmafibrinogeenvlakke. Dit is aangetoon dat swart Suid-Afrikaanse bevolkingsgroepe 
' n hoer plasmafibrinogeenvlak in vergeleke met Europeers het, wat 'n moontlike 
bydraende faktor tot die hoe risiko vir beroertes in die populasie kan wees. In hierdie 
studie word die hipotese dat 'n toename in die inname van vitamien A, plasmafibrinogeen 
verlaag, ondersoek. Hierdie studie vonn deel van 'n kliniese ingreepstudie ll1 
gekontroleerde toestande, om die effek van vitamin A gefortifiseerde suiker op 
plasmafibrinogeen van Suid-Afrikaanse swart vroue, 13-25 jaar oud, te ondersoek. 
Die metodologie sluit vraelyste in om die demografiese profiel, suikerverbruik en 
aanvaarbaarheid te bepaal. Meetinstrumente sluit in 'n dubbele basislyn antropometriese 
en biochcmiese bepalings op 95 proefpersone in ' n ewekansige steekproef populasie. 
Proefpersone is verdeel in 'n eksperimentele groep (n=46) wat gefortifiseerde suiker 
gebru ik het (80 IU vitamien A per gram suiker), en 'n kontrole groep (n=49) wat plasebo 
suiker gebruik het. Bepalings is op 4, 8 en 12 weke van verbruik herhaal. Plasmavlakke is 
deur 'n Dade Behring - Multifibren® U metode bepaal. Die metode is 'n aangepaste 
Clauss metode. 
Die resultate van basislynbepalings van plasmafibrinogeenvlakke was as volg: 5.1 % van 
die proefpersone het 'n fibrinogeenvlak minder as 2.71 gil gehad, 83.8% van die 
proefpersone 'n fibrinogeenvlak tussen 2.72 en 3.30 gil en 11.1% van die proefpersone 'n 
plasmafibrinogeenvlak van meer as 3.30gfl. 
Basislynbepalings van serum vitamin A vlakke het getoon dat 12% van die respondente 
'n vlak van meer as 30 ~gldl gehad het, 33.7 % 'n vlak van tussen 30 en 40~gldl, 38.6% 
'n vlak van tussen 40 en 50~gldl en 15.7% van die respondente 'n serum vitamin A vlak 
van meer as 50~gldl. 
Gedurende die proefperiodes het die populasie gemiddeld 60g suiker per dag gebruik. 
Dit het 'n addisionele 4800 IU of 1446 ~g RE vitamin A aan die eksperimentele groep 
voorslen. 
Die resultate het getoon dat die gemiddelde plasmafibrinogeenvlakke van die 
eksperimentele groep betekenisvol verminder het vanaf die basislynresultate (2.81 giL). 
Na 4 weke van die intervensie was dit 2.64 giL en 8 weke 2.65 giL. Waardes het egter 
weer toegeneem tot op basislynvlak tydens week 12 (2.84 giL). Die kontrolegroep se 
resultate toon toename in gewig tydens week 12. Daar word gespekuleer dat die toename 
in gewig moontlik verantwoordelik was vir die toename in plasmafibrinogeenvlakke. 
As resultaat van die studie word tot die gevolgtrekking gekom dat die inname van 
gefortifiseerde suiker wat addisionele vitamien A verskaf het in die dieet van die 
proefpersone, plasmafibrinogeenwaardes betekenisvol venninder het tydens weke 4 en 8. 
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Die aanbeveling word gemaak dat toekomstige studies die effek oor 'n langer peri ode, 
met proefpersone wat ' n hoe plasmafibrinogeenvlak en 'n lae vitamien A status 
het,behoort te ondersoek. 
Hierdie resultate is reeds aangebied sien: ......... ....... annexnre 12 
Sluitelwoorde: Fibrinogeen, vitamien A fortifisering 
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Chapter 1 
The problem and its setting 
1.1 Introduction 
The clear association between high fibrinogen levels and the risk of cardiovascular 
disease (CVD) is of increasing practical relevance as well as scientific interest. The 
relationship was first reported in preliminary results from the Northwick Park heart study 
in 1980 (Meade et ai. , 1980: 1 050). 
Numerous other prospective studies have almost without exception confirmed a strong 
and independent effect of raised plasma fibrinogen in both the onset and progression of 
ischaemic heart disease (lHD), stroke and lower extremity arterial disease . As evidence 
accumulates to implicate fibrinogen as a risk factor for CVD, it becomes important to 
characterise the levels and correlates of fibrinogen in diverse populations. Knowledge of 
the correlates of fibrinogen can contribute to disentangle the independent contribution of 
elevated fibrinogen concentration to CVD (Folsom, 1995:21). 
Changes in coronary heart disease (CHD) have been linked with dietary changes during 
war years and have been advanced as evidence supporting the diet-lipid-CHD hypothesis. 
It seems unlikely, however, that diet could have such a rapid effect in modifying 
mechanisms that lead to atherosclerosis. Furthermore, a number of prospective studies 
have shown relationships between diet and CHD mortality even after adjusting for serum 
cholesterol levels . It seems likely that mechanisms other than those that involve lipid 
infiltration could link diet and heart disease. In particular, the relationship between 
nutritional variables and haemostatic factors (Rogers dJil., 1988: 197) is thought to 
contribute to this link. 
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1.2 Motivation 
In the face of the present HIV I AIDS epidemic in many countries, it is unlikely that their 
fragile economies will be able to cope with a major epidemic of CVD, unless emphasis is 
shifted from secondary treatment to primary prevention of risk (James et aI. , 2000:384) . 
Due to changes in the political dispensation, the African population of South Africa is 
under a rapid urbanisation process (ANON, 1998:200). The increase in hypertension and 
stroke rates of urban Africans have been well described (Bradshaw i!.1...JJl., 1999:40), but 
less is known about the influence of diet and lifestyle on plasma fibrinogen levels (James 
et al .. 2000:384), one of the major risk factors for stroke. For prevention of stroke, it 
therefore seems important to examine factors that influence plasma fibrinogen levels of 
Africans. 
1.3 Problem statement 
Murray and Lopez (1996:350) point out that in 1990, IHD was the number one cause of 
death worldwide with cerebrovascular disease (CY A) in second place. They estimated 
that these two would remain first and second leading causes of death in the year 2020, 
mainly because of increased prevalence in developing countries. 
Steyn (1992:20) indicated that chronic diseases of lifestyle and their risk factors have 
major impact on disease patterns in South Africa. It is suspected that as infectious 
diseases are controlled in developing sectors, chronic diseases of lifestyle will become 
more common. These chronic diseases include CHD, stroke, hypertension, type 2 
diabetes mellitus and some cancers. 
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Table 1 Leading causes of death in rural areas of South Africa· 
RANK AGE6ROUP 
35-54 years 55-74 years " 75 years 
1 Assault 10% eVA 1I % IHD 1I % 
2 eVA 8% IHD 9.2% eVA 6% 
3 Motor accidents 7% Pulmonary tuberculosis 9% Pulmonary tuberculosis 4% 
4 AIDS 6% Genito~urinary cancer 3.3% Diarrhea 3% 
5 IHD5% Motor accidents 2.9% Gastro-intestinal cancer 2% 
• In the rural areas of South Africa, the Agincourt study from 1992 to1995 the leading 
causes of death by selected age groups are as shown in table 1. Adapted from Fritz 
(1997:585); The Argincourt study, (1992-1995). 
If one accepts the hypothesis that elevated plasma fibrinogen levels are causally linked to 
atherogenesis and to its thromboembolic complications, lowering fibrinogen levels 
should retard the atherosclerotic process and reduce cardiovascular events, which is of 
considerable clinical and public health interest (Markowe &Q1., 1985: 1313). 
There is some but not conclusive evidence that low vitamin A status may be associated 
with raised plasma fibrinogen (reviewed by Vorster e/ aI., 1997(b):683). It is also known 
that South African children have a problem of vitamin A deficiency as indicated by the 
SA VACG study results (SA VACG, 1995:335). A meta-analysis of available literature 
showed that black South African adolescents and adults generally have lower than 
recommended intakes of vitamin A (Vorster tl.iJl..., 1997(b):683). 
Therefore, Africans with low vitamin A status, high fibrinogen levels (Vorster l!Ll1L 
1998: 170) and high stroke incidence and prevalence (reviewed by James el al., 2000:390) 
should be an appropriate group to examine the hypothesis that increased intake of vitamin 
A will lower plasma fibrinogen levels. 
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1.4 Purpose of the study 
1.4.1 Objectives 
The major objective of this project was to examine the effects of sugar fortified with 
vitamin A in young, black South African females aged 13 to 25 years in a placebo-
controlled clinical trial on plasma fibrinogen levels. 
1.4.2 Subsidiary objectives 
The subsidiary objectives were to establish in the same sample population, the following: 
a) What is the vitamin A status of the young African females in the Vaal 
Triangle? 
b) What is the fibrinogen status of the young African females in the Vaal 
Triangle? 
c) Is there a correlation between vitamin A status and plasma 
fibrinogen levels? 
d) Is there a correlation between plasma fibrinogen levels and white cell count? 
e) Is there a correlation between plasma fibrinogen levels and red cell parameters 
(Red cell count (REC), haemoglobin (Hb), haematocrit (Hct), and mean cell 
volume (MeV)? 
f) Is there a correlation between plasma fibrinogen levels and iron status parameters 
(iron, ferritin, transferrin, and soluble transferrin receptors)? 
g) Is there a correlation between plasma fibrinogen levels and BMI? 
1.5 Research methodology 
1.5.1 Literature study 
A literature study was done using sources at the Vaal Triangle Technikon library as well 
as the Ferdinand Postma Library at the Potchefstroom University. 
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The following areas were included in the literature study: 
• Vitamin A deficiency: globally and in South Africa 
• Food fortification with vitamin A 
• Fibrinogen structure 
• Fibrinogen physiology 
• Fibrinogen pathophysiology 
• Epidemiological studies on fibrinogen status: globally and in South Africa 
• Interaction between vitamin A and fibrinogen 
1.5.2 Empirical research 
A double blinded, "placebo"·controlled trial for 12 weeks in young African women, aged 
13-25 years was conducted, with sugar fortified with vitamin A as intervention and 
plasma fibrinogen as outcome. 
Validated questionnaires were used to determine demographic profiles, food consumption 
patterns and compliance of fort ified sugar consumption nr placebo sugar during the trial. 
Anthropometry and double baseline biochemical measurements were done on 95 
randomly selected subjects. Measurements were repeated after 4, 8 and 12 weeks of sugar 
consumption. 
Anthropometry measurements included: 
• Weight I Height and waist hip circumferences to determine the body mass index 
(BMI) and W:H ratio 
Biochemical measurements included: 
• Serum vitamin A levels (10 ml clotted blood, light protected). 
• Plasma fibrinogen levels (5ml citrated blood (lpart sodium citrate (0.11 mol/l) 
with 9 parts venous blood)). 
• 5ml Blood in an EDTA tube (purple lid) for full blood count 
• 10 ml blood in a silicone-coated tube for preparation of serum for the analysis of 
iron, ferritin, transferrin and soluble transferrin receptor (sTrF). 
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1.5.3 Subjects: 
A random sample of 100 African women volunteers aged 13-25 was selected using the 
following sampling procedures: The Vaal Triangle population was divided into groups, 
consisting of the different towns in the Vaal Triangle. The names of the suburbs per town 
were thrown in a hat and drawn. Thereafter the names of all the schools, tertiary 
institutions and clinics in the selected suburbs were thrown into a hat. One school or 
tertiary institution and one clinic per suburb were drawn from the hat to form part of the 
sample population. 
The sample population of 100 was then randomly divided into an experimental (n=46) 
group consuming fortified sugar (80 IU vitamin A per gram sugar), and a control group 
(n=49) consuming non-fortified sugar. 
1.6 Contribution of author to the study 
This project was a team research project Dr. Wi Ina Oldewage-Theron co-ordinated and 
administrated the project as project leader. This study was also an under-study of Dr. 
Wilna Oldewage-Theron 's Ph.D. study. Ms. Emsie Dicks studied the compliance and 
consumer acceptability of the fortified sugar. Ms. Mosa Selepe did the nutritional data 
gathering and analyses. Mr. Jose van Rensburg assisted in blood analysis. 
The author's contributions to the study were: . 
• Standardising laboratory infrastructure (Apparatus placements, reagent purchasing, 
and apparatus calibration). 
• Training of the nursing sister for fieldwork. 
• Management of the laboratory test procedures and quality control program. 
• Co-ordinate consigns of the vitamin A samples. 
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1. 7 General outline of the thesis 
Chapter 1: Problem statement and its settings 
This chapter includes a brief discussion covering the motivation of the study, the problem 
statement, research objectives and aims as weB as research methodology. 
Chapter 2: Literature review 
In chapter two an analysis of the literature regarding fibrinogen, vitamin A, fortification, 
and possible interactions between vitamin A status and plasma fibrinogen was made. 
Chapter 3: Methodology 
In this chapter the study design, experimental subjects and different methods used in this 
study are discussed. 
Chapter 4: Results and discussion 
In chapter four the results are given and compared to findings of other studies. 
Chapter 5: Conclusions and recommendations 
The results of the study are interpreted in chapter 5. Conclusions are drawn and 
recommendations regarding the intervention of fortified vitamin A on plasma fibrinogen 
levels of the sample population made. The need for further research is indicated. 
, 
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Chapter 2 
Literature review 
2.1 Introduction 
Smith (1995:11) reported that Rokitansky (1852) described the atheromatous process and 
suggested that the deposit is a product derived from the blood and for the most part from 
fibrin of the arterial blood. In 1946 Duguid demonstrated that fibrin existed both within, 
and on the surface of apparently intact fibrous plaques. Meticulous histological studies 
demonstrated thrombotic occlusion, frequently associated with plaque rupture, in most 
necropsies with myocardial infarction. In 1952 Gilchrist and Tulloch, studying patients 
with acute MI in the Edinburgh Royal Infirmary, reported for the first time elevated 
plasma fibrinogen levels in patients with arterial disease. 
Since the discovery of the importance of micro nutrients, intensive research has provided an 
appropriate perspective regarding some aspects of their essentiality as well as their role in 
relation to the prevention of disease. It is realised today that micronutrients not only protect 
against deficiency diseases, but are al so involved in the prevention of some chronic, 
degenerative diseases. However the relationship between micronutrient status and plasma 
fibrinogen, as well as the consequences of raised fibrinogen levels have not been studied in 
detail. 
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2.2 Fibrinogen 
2.2.1 Historical background 
An understanding of the fibrinogen molecule, its structure, synthesis and function is 
necessary in order to analyse its independent contribution to CVD, as well as to improve 
CVD risk assessment and intervention. 
Blomback (2001 :1) in a keynote address at the 16th International Fibrinogen Workshop 
gave a historical review on fibrinogen research. He stated that the observation of the 
coagulation of blood could be traced back to early historical times. In about 300 BC 
Aristotle declared that blood clotting was similar to freezing of water; blood clot when 
energy from the heart dissipated. It was associated with death. Galen, the teacher of 
humoral pathology, described the phenomenon that in many states of disease, clotted 
blood had a whitish cap on top of red cells. Galen thought it was due to an excessive and 
dangerous secretion of one of the four humors, the phlegm. It was only in the 17th century 
that Malpighi described a clot as a white fibrous substance obtained from a "red cell clot" 
after washing with water. In 1770 Hewson showed that coagulation takes place in plasma. 
Deni de Com mercy proposed in 1859 that there existed a precursor of fibrin that he called 
fibrinogen. Fibrinogen transforms into fibrous fibrin by a process called denaturation. 
Alexander Schmidt indicated that a "thrombic" enzyme was involved in fibrin formation. 
Olof Hammersten prepared a highly purified form of fibrinogen from horse plasma 
through precipitation with salt. Hammersten's preparation did not clot spontaneously but 
required the addition of a 'thrombotic enzyme". Then came a lull in fibrinogen research. 
In the 1940s and 1950s numerous measurements of electrophoretic mobility, 
sedimentation and diffusion constants, osmotic pressure, intrinsic viscosity, flow 
birefringence and light scattering were made on fibrinogen, especially by American 
investigators. From different physicochemical measurements, a picture of the fibrinogen 
molecule as a prolate ellipsoid emerged. This model had a length of 500-700 A and axial 
ratio of 5-20 A. Molecular weight varied considerably but the most reliable was 
considered to be 330-340 kDa. 
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By the end of 1970 the major architectural features as well as the complete covalent 
structure of fibrinogen, was known. Recent crystallographic studies in the laboratories of 
Davie, Doolittle, and Cohen have not only confirmed the early interpretations of 
fibrinogen structure and function, but have also given exciting additional information at 
the atomic level. 
The role of fibrin as a structural element in pathological thrombi had been evident since 
Virchow's time. Reports on the interaction of fibrinogen or fibrin with cellular elements 
started to emerge in the 1980s. Epidemiological studies have shown that an increase in 
plasma fibrinogen levels is a risk factor for ischaemic heart disease. High fibrinogen 
levels cause tight network structures during clotting. These structures are elastic, with 
thin fiber strands, and therefore brittle. Such structures are believed to be thrombogenic. 
Low fibrinogen levels give rise to plastic structures that deform in flow, considered as 
nonthrombogenic. 
A new fibrinogen analogue, with a molecular weight of 420 kDa, has been discovered. 
This interesting protein is fully clottable. However, it is present in very low 
concentrations (1-4% of total fibrinogen) and its role in physiology is far from enigmatic. 
2.2.2 Structure of Fibrinol:en 
Human fibrinogen is a large glycoprotein encoded on chromosome 4, with a mass of 
approximately 340 000 Da. It is composed of three pairs of non-identical polypeptide 
chains (u (alpha), fl (beta), y (gamma» joined together by disulfide bonds (Lip, 
1995:ISS). The major characteristic is a slightly bent and twisted long tri-nodular shape. 
It has a half-life of 3-4 days (Resch & Ernst, 1994: 170). 
Fibrinogen molecules are elongated 4S-nm structures consisting of two outer D domains; 
each connected by a coiled-coil segment to a central E domain (see figures 1 and 2). It 
has six polypeptide chains of three types: two Au, two BP and two y chains, which are 
joined together within its N-terminal E domain by S symmetrical disulfide bridges, one 
pair at position Au28, two pairs between Au36 and Bp6S, and a third set between y8 and 
y9 positions (Moses son e.LQL 2001:13). Biochemical and immunological studies have 
shown that the central globule (fragment E) comprises the aminoterminal ends of all six 
polypeptide chains, whereas the distal globules (fragments D) are composed of the more 
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carboxyl-terminal regions of the chains. The Aa chain consists of 61 O-amino acids, the 
BP chain 164-amino acids and the majoryA 41 I-amino acids (Mosesson, et ai. , 2001 :13). 
From a review of relevant literature, Iacoviello et ai. (1998:270) concluded that 
polymorphism in coagulation factor genes contribute to the variability in plasma levels of 
clotting factors within their range of distribution. It was also mentioned that the 
polymorphism contributes to the risk of CVD by influencing a person' s response to 
environmental risk factors. 
Most of the body's fibrinogen is found in plasma. It exists as a population of slightly 
different molecules (Blomback, 1996:30). The major fraction of ± 50% is high 
molecular weight fibrinogen (HMW, 345 KD), followed by ± 40% low molecular weight 
fibrinogen (LMW, 300 KD). The remaining fractions are LMW fibrinogen (280 kD) and 
fibrinogen 420. Fibrinogen 420 (1-4% of total fibrinogen) ,"contains two extended a chain 
isoforms (aE) (Grieninger et al., 1997:2610). 
Fibrinogen 
D domain 
FPB 
FPA 
E domain Yj 
I i 
platalets 
I ' I 398 
QQHHlGG AKa VRPEHPAETEYD SL yP EOOL 
t .. 11 427 
Figure 1 
lUI,... l'"!o .... 
QQHHLGGAKQAGOV 
398 t • 411 
:a.. III, 
Schematic diagram of fibrinogen showing the major structural domains, 
the association sites that participate in fibrin polymerization and 
crosslinking, and other molecular and cellular binding interactions 
(adaptedfrom Mosseson et al., 2001:12) 
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Fragment DD 
Coiled-coil Coiled-coil 
Fragment D I I Fragmenl 0 Central Domain 
Figure 2 Native fibrinogen showing proposed knob-hole connections (adapted 
from Doolittle et af .. 2001:37) 
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2.2.3 Production of fibrinoeen 
Fibrinogen is synthesised by the hepatocyte, and subjected to positive feedback of its own 
degradation products and certain cytokines such as IL-6, which together are called 
hepatocyte stimulating factors (HSF) (Vasse e..I...JJL., 1996:332). Vasse et al. (1996:332) 
found that IL-4 and IL-13 added to Hep G2 cells decrease the secretion of fibrinogen 
released into the Hep G2 conditioned medium. This effect was related to a decrease in 
mRNA expression for fibrinogen. The effect of IL-IO was less intense and only 
evidenced by a decrease in expression of fibrinogen mRNA. 
2.2.4 Function of fibrinoeen 
Circulating fibrinogen comprises a heterogeneous family of closely related molecules that 
are soluble and which share the ability to form a fibrin gel via a series of molecular 
events (Nieuwenhuizen, 1995:6). Fibrinogen is the key protein of the blood coagulation 
cascade (see figure 3). The first process involves the formation of a temporary and 
unstable clot by the platelets. Thereafter, platelets are equipped with fibrinogen receptors. 
Finally fibrinogen stabilises the clot in order to stop bleeding. (Resch & Ernst, 1994: 170). 
Circulating plasma fibrinogen, the coagulation and fibrinolytic systems: 
Fibrinogen influences blood flow by determining blood viscosity, red cell, leukocyte and 
platelet adhesiveness and aggregability (Vorster, 1999: 139). 
Fibrinogen is furthermore essential for wound healing, to such an extent that artificial 
fibrinogen is produced to be utilised in a variety of clinical arenas (cardiovascular and 
other major surgery, especially for patients with haemostatic disorders) (Am rani e..I...JJL., 
200\:566). 
Fibrinogen is also an important acute phase reactant. Levels can rise 2-20 fold with acute 
stress, such as infection surgery, etc. (Folsom, 1995:22). 
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Plasma fibrinogen and the eoaguIatiOD 
and fibrinolytic: systems: 
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Figure 3 The role of plasma fibrinogen in the coagulation and fibrinolytic system 
(Adapted from Lip, 1995:155) 
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2.2.5 Determination of fibrinoeen 
Several methods are available, but the molecular heterogenecity of fibrinogen (and other 
plasma factors) can influence the results of these assays to different extents 
(Niewenhuizen, 1995:6). Previously the lack of a WHO standard for fibrinogen limited 
inter-laboratory comparisons, because of differences in absolute values (Meade, 
1997:14), but an international fibrinogen standard is now available (Gaffney & Wong, 
1992:431) 
a) Clotting Rate 
The most frequently used method is that of Yon Clauss (Yon Clauss, 1957:231-237): The 
time between the addition on thrombin to plasma and clotting is recorded. The excess 
amount of thrombin chosen ensures that the clotting time depends on the plasma 
fibrinogen levels. A calibration curve is usually compiled by a series of diluted standard 
values. Plasma is obtained when anticoagulant is added during collection of blood in 
order to prevent coagulation. After separation the 55% fluid portion on top of the blood is 
called plasma (Brown, 1988: 1) 
SHORTCOMING: The heterogeneities of fibrinogen of the patient (subject) may differ 
from the calibration material, and may cause variability in the clotting time of the plasma 
sample (LMW fibrinogen clots slower than HMW fibrinogen). Other factors may also 
influence the results. Increases in blood sialic acid content, such as found in liver 
cirrhosis, may cause an increase in the clotting time of the sample. Increased levels of 
antipolymerising FOP's (O-dimer, and fragment X and Y), will prolong the clotting time 
and thus appear to lower the fibrinogen levels (Niewenhuizen, 1995:7). 
b) Turbidity 
This method is based on the change in turbidity when fibrinogen clots, detectable at a 
wavelength of 300nm (Ellis &' Stransky, 1961 :480). 
SHORTCOMING: Any factor that will influence the structure and, therefore also the 
turbidity, will influence results (HMW/LMW/LMW' ratio). The concentration of calcium 
ions present in the sample may also playa very important role (Niewenhuizen, 1995:8). 
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c) Precipitation 
Fibrinogen can be precipitated from plasma by heating at 56°C, or by adding salts such 
as sodium sulphite. 
SHORTCOMING: A non-specific method that can be influenced by other plasma proteins 
(Niewenhuizen, 1995 :8). 
d) Immunological methods 
Polyclonal antibodies are used to detect fibrinogen 111 assays such as radial lmmuno 
diffusion and Laurell rocket immunoelectrophoresis. 
SHORTCOMING: These methods are not specific for fibrinogen but also detect 
fibrinogen derivatives such as soluble fibrin and FDPs. 
DEVELOPMENTS: Enzyme immunoassay methods have recently been developed that 
are specific for the total HMW and LMW fibrinogen molecules. These methods do not 
detect soluble fibrin, LMW' and FDPs. Time-to-result duration is only one hour 
(Niewenhuizen, 1995 :8). 
e) Clottable protein 
Thrombin is added to a plasma sample, which is then allowed to clot exhaustively. The 
clotted proteins are collected and washed extensively. The mass of the clot is assayed, 
directly by weighing or indirectly by dissolving in urea and the optical density (OD) 
measured at 279nm. In another version, the OD can be taken at 315 nm to compensate for 
contaminants such as entrapped lipids. 
SHORTCOMING: The heterogeneities seem to have no or little effect on this procedure. 
This procedure is however, time-consuming and laborious (Niewenhuizen, 1995:7). 
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2.2.6 Fibrinoeen and cardiovascular diseases: PathophysioloeY of 
fibrinoeen 
Evidence exists that fibrinogen is involved in early local atherosclerotic changes of the 
vessel wall. Experimental de-endothelialised arterial segments indicated that fibrinogen is 
integrated directly into the vascular lesion, where it is converted into fibrin and 
fibrinogen degradation products and promotes the formation of thrombi in a dose-
dependant manner (Resch & Ernst, 1994:171). The same authors reviewed the evidence 
that a dose-dependant stimulating effect seems to exist on: 
• The migration of smooth muscle cells 
• The proliferation at the site of the lesion 
• The permeability for proteins which leads to accumulation of low-density lipoproteins 
• The enhancement of the adhesives of white blood cells, which is pathologically 
relevant in microcirculation 
Monocyte activation could playa central role in atherugenetic pathogenesis by inducing: 
• The expression of tissue factor and plasminogen activators responsible for fibrin and 
fibrin degradation products formation which are mitogenic for smooth muscle cells 
(Vasse e1.JJL., 1996:332). 
• The production of cytokines (IL-6, Oncostatin M (OSM), Leukaemia inhibiting factor 
(LIF)), stimulating the fibrinogen production by the hepatocyte with different 
efficiency (Vasse fLfJL., 1996:332). These cytokines are also responsible for vessel 
injury, whereas cytokines such as IL-4, IL-IO, IL-13 , which protect vessels against 
injury, are capable of antagonising (in vi/raj the increase in fibrinogen induced by 
inflammatory factors (Vasse fll..S!l, 1996:335). 
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Mechanisms through which increased plasma fibrinogen levels promote ischaemic 
events (seeflgure 4): 
• Atherogenic: 
Fibrinogen may infiltrate the arterial wall where it can be converted to fibrin. Within the 
arterial wall, fibrin binds to low density lipoprotein and is converted into degradation 
products which stimulate smooth muscle cell proliferation as well as the uptake of lipids 
by macrophages (Smith, 1995: 12). 
• Determinants of whole-blood and plasma viscosity: 
The total peripheral resistance is composed of a vascular and a viscous component (Resch 
& Ernst, 1994: 170). 
Fibrinogen is an important determinant of plasma viscosity and red cell aggregation and 
hence, of whole blood viscosity (Lowe & Rumley, 1999:92) due to its slightly bent and 
twisted long tri-nodular characteristic (Resch & Ernst, 1994: 170). Raised levels of 
elongated high molecular weight fibrinogen increase viscosity which, in the presence of 
peripheral arterial narrowing, is associated with the risk of intermittent claudication, 
reduced perfusion pressure and reduced microcirculatory blood flow. Therefore, elevated 
plasma fibrinogen may promote atherogenesis, thrombogenesis and ischaemia, through 
its rheological effects (Lowe~, 1993: 1920). 
• increased platelet aggregation and thrombus formation: 
Increased plasma fibrinogen levels may be thrombogenic, by promoting platelet 
aggregation, as well as, fibrin formation. 
• Fibrin thrombus structure, deformability and lysability: 
High plasma fibrinogen levels are associated with an increased tendency to form an 
increased size of fibrin thrombi. Alteration of the structure of the fibrin clot reduces the 
Iysasibility of the fibrin thrombi (Ernst & Resch, 1993:960). 
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Diagram of some of the fibrinogen, thrombin and fibrin interactions 
that may be involved in growth of atherosclerotic lesions (adapted from 
Smith,1995:12) 
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In the Scottish Heart Health Study (SHHS), persons with a family history of heart disease 
or personal history of high blood pressure, diabetes, stroke, or presence of intermittent 
claudication all had higher plasma fibrinogen concentrations than those without as 
indicated in Table 2 (Lee e1.JlL 1993:338). 
Table 2: Evidence from SHHS of correlation between CHD and increased 
plasma fibrinogen levels 
History Plasma fibrinogen level (gIL) and standard deviation 
Male 
None 2.27(0.01) 
Myocardial infarction 2.51(0.02) 
Angina 2.45(0.02) 
Values Differ significant at p <O. 001 
SHHS: Scottish Heart Health Study 
CHD: CoronOlY heart disease 
Female 
(n=3367) 2.34(0.01) (n=3096) 
(n=248) 2.63(0.04) (n=72) 
(n=394) 2.50(0.02) (n=398) 
In assessing the imporlance of fibrinogen, viscosity, and white blood cell count as risk 
factors for ischaemic heart disease results were obtained in the Caerphilly and Speedwell 
collaborative Heart studies are indicated in Table 3 (Yarnell et al., 1991 :838). 
Table 3: 
Test 
Caerphilly and Speedwell collaborative Heart studies - the importance 
of fibrinogen, viscosity, and white blood cell count as risk factors for 
ischaemic heart disease (IHD) 
lncideuce Age and area -standardized 
difference 
No major'lHD Major IHD Mean 95%CI 
(n=4408) (n=233) 
Fibrinogen (gIl) 3.66±0.82 4.09±0.92 0.38 0.28-0.49 
Viscosity (cp) 1.688±0.096 1.735±0.099 0.045 0.032-0.057 
WBC (10911) 7.02±2.01 7.86±2.22 0.84 0.57-1.10 
40 
© Central University of Technology, Free State
Sanchez-Bayle fLJJ.L (1993:325) studied the correlation between plasma fibrinogen 
concentration in Spanish children and adolescents, and their family hi story for stroke and 
IHD. Children with a family history were found to have a significantly (p<0.05) higher 
plasma fibrinogen than the group without a family history. 
Meta-analyses of prospective stud ies indicated that individuals in the upper third of the 
plasma fibrinogen distribution have about twice the risk of ischaemic heart disease or 
stroke compared to individuals in the lower third. This increased relative risk is similar in 
both sexes, and in individuals with or without baseline evidence of CVD. From the above 
evidence it seems that fibrinogen adds to ri sk factors of major cardiovascular predictive 
such as smoking, blood pressure and serum cholesterol (Lowe & Rumley, 1999:92). 
Therefore measurements of plasma fibrinogen could improve the assessment of CVD 
risk. 
In the FINRISK haemostasis study fibrinogen and Lp (a) were associated with prevalent 
CHD in a Finnish population (Salomaa!U.1!L, 1994: 1293). 
The 20-year follow up of the Framingham Heart Study revealed that fibrinogen had a 
powerful effect on initial cardiovascular events in men and in women, but that it 
influenced recurrent events only in men. This study also showed that the magnitude of 
risk diminished with advancing age in women (but not in men) and that fibrinogen was a 
stronger risk factor in men than in women (Kannel !ll....fJL, 1996:91). The SHHS showed 
that fibrinogen was a strong predictor of fatal, nonfatal, new or recurrent CHD, and of 
death of unspecified cause in both men and women (Woodward!U.1!L, 1998:60). 
A number of clinical trials indicated that in both men and women, a plasma fibrinogen 
level of 2.8 to 3.00 gil may already be associated with a modest trend towards an 
increased CHD risk (Becker et ai" 1996: 145). 
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2.27 Factors influencing fibrinogen levels 
a) Fibrinogen and socioeconomic conditions 
The Whitehall study of British civil servants (1967) showed a steep inverse association 
between social class, as assessed by grade of employment, and mortality from a wide 
range of diseases. The Whitehall II study investigated (between 1985 and 1988) the 
degree and causes of social morbidity in a new cohort of civil servants. An inverse 
association between employment grade and prevalence of angina, ischaemia and 
symptoms of chronic bronchitis was found, which persisted over a period of 20 years 
(Marmot !ll.....JJ.L, 1991:1387). Adult plasma fibrinogen concentration was inversely 
associated with childhood environmental factors (adult height, father's social class, and 
educational participation) (Brunner f.1...J1L 1996: 1 008). Lower socioeconomic status (as 
shown by employment grade) was associated with higher fibrinogen concentrations. 
These findings are believed to be a marker of the biological pathways that mediate the 
inverse socioeconomic gradient in coronary disease (Brunner ~. 1996: 1008). The 
Kuopio Ischaemic Heart Disease Risk Factor Study confirmed observations of an inverse 
association between plasma fibrinogen concentration and socioeconomic conditions, by 
utilising five socioeconomic indices (lifetime occupation, education, income, ownership 
of material possessions, and childhood socioeconomic status) in middle-aged Finnish 
men (Wilson et at. 1993 :292). Markowe et al. (1985: 13130) showed that between grades 
of employment significant differences in plasma fibrinogen concentration existed but 
found no difference in clotting factor ll, VII, VIII, and X. 
The causes of higher plasma fibrinogen levels in lower socio-economic strata are not 
clear. It could be related to environmental factors such as the smoking habits, nutritional 
status and/or low-grade infections 
b) Seasonal changes 
Higher plasma fibrinogen levels occur 111 winter compared to levels in the summer 
(Meade, \995:33). Variation in fibrinogen levels can be 5-20% higher in winter than in 
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summer. There are speculations that higher fibrinogen levels in winter may reflect either 
increased body temperature or an acute-phase response to respiratory infections. It has 
also been speculated that the increased death rate from ischaemic vascular disease in 
winter is due to increased plasma fibrinogen levels (Folsom, 1995:24). 
Van der Born eLI!.L (1994: 18) indicated that in the Rotterdam study a 0.32g11 higher 
fibrinogen level (adjusted for age, gender and smoking) occurred in winter than in 
summer. The difference was greater in subjects 75 years and older (0.42g/l) than in those 
aged 55-74 years (0.28 gil) . Platelet count and body mass index were also higher in 
winter. Surprisingly, leucocyte count was lower in the winter than in summer (possibly 
due to a higher incidence of viral infections). 
Crawford tU...11L (2000:23) also found that significant seasonal rhythms were present for 
fibrinogen (amplitude 0.08g/l, peak May/June, p=0.05). 
c) Diet 
There exists some controversy 111 the literature about the effect of diet on plasma 
fibrinogen levels. Meade (1997:13) is of the opinion that fairly extensive evidence exists 
that fat, carbohydrate and fibre do not influence fibrinogen levels, at any rate in the short 
term. Equivocal evidence exists on the lowering effect of fish oi I on plasma fibrinogen 
levels. Lee et al. (1990:915) reported that in the Scottish Heart Health Study, one of the 
first population based reports, that high fish consumption, especially of white fish, was 
weakly associated with elevated fibrinogen levels. From numerous study results it can 
however been concluded that although fish oil may inhibit platelet aggregability and 
lower some coagulation factors , it may also impair the fibrinolytic potential by lowering 
tPA and raising PAI-I (Vorster et al .. 1997:677). 
Rogers gL11L (1988: 199) indicated that total daily fibre intake was negatively associated 
with fibrinogen levels. 
Cepelak eLI!.L ( 1991) indicated that a low-energy diet could improve the fibrinolytic 
profile of patients with a deep-vein thrombosis with up to 50%. 
Comparing two groups of Africans, it was found that the group who had a higher fat 
intake had a higher fibrinogen level than the group with lower fat intake; this group also 
had a higher fibre and lower cholesterol intake (Vorster et aI., 1997:674). 
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Blaberg l1.i!L(l995:240) showed that a diet rich in stearic acid compared with one rich in 
myristic plus lauric acids increased plasma fibrinogen levels. 
Very few studies have reported effects of vitamins on coagulation . It has, however, been 
reported that in healthy elderly women who took micronutrient supplements, higher 
levels of serum vitamin A, retinol binding protein , pyridoxal and pyridoxal phosphate 
were associated with lower plasma fibrinogen levels (Kruger e.LJJl..., 1994:112). The 
MONICA study has also shown that low plasma retinol levels were associated with 
higher fibrinogen levels and impaired fibrinolytic activity (reviewed by Vorster !il....Jll., 
1997:678). Delport (1999:14) also found that risk of CHD associated with vitamin A 
deficiency was notably higher compared to that associated with the deficiency of other 
anti-oxidative vitamins. 
Increased intake of vitamin E results in decreased fibrinogen levels. When vitamin E is 
added to polyunsaturated fatty acids (PUFA ' s) it also results in decreased fibrinogen 
levels. The monounsaturated oleic acid, and the saturated palmitic acid decreased 
fibrinogen secretion , both alone and in combination with vitamin E. Vitamin E may have 
these effects by preventing the oxidation of PUFA's (Vorster rr.m.., 1997 :678). 
There is evidence that specific food or substances may also have an effect on other 
haemostasic factors. Strongly flavoured foods such as onions, chilies, and spices, as well 
as green tea may increase fibrinolytic activ ity (Vorster et ai., 1997 :678). 
The THUSA study of Africans in the Northwest province of South Africa (James ll1\L., 
2000:392), showed that subjects with the highest intakes of dietary fibre, plant proteins, 
vitamin E, and iron and with the highest PIS ratio; and with the lowest intake of trans 
fatty acids and animal protein had the lowest plasma fibrinogen. These results suggested 
that a low nutritional status could be associated with high plasma fibrinogen. James f1..!Jl. 
(2000:386) found significant differences per fibrinogen quartile of some biochemical 
variables indicative of nutritional status. In both men and women, small but significant 
increases in serum calcium and magnesium were associated with a rise in plasma 
fibrinogen. Similarly, higher total serum protein and globulin levels were assoc iated with 
higher fibrinogen , whereas significant decrease in vitamin E and vitamin B6 were 
associated with increased plasma fibrinogen levels. A decrease in serum iron and 
percentage saturation of transferrin was also associated with higher fibrinogen levels. 
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The associations between high plasma fibrinogen and low iron status (James tl.J!L, 
2000:392) further support the hypothesis that under- nutrition is associated with high 
fibrinogen levels. 
d) Physical activity 
Strenuous exercise is associated with lower plasma fibrinogen levels. A difference of 
15% in the risk of IHD, compared to sedentary lifesty le, has been reported. These results 
were derived from the Caerphilly Prospective Heart Study, SHHS and Gothenburg study 
(reviewed by Lip, 1995 :160). 
During the SHHS, Lee tl.JlL (1990:915) indicated that the inactive in leisure group had 
higher fibrinogen levels. Females who claimed to be inactive at work had higher values 
than the average or active groups. Individuals indicating that they had reduced their level 
of physical activity over the previous year also had elevated fibrinogen levels. 
A study of 51-year-old men I iving in the county of Copenhagen, showed that there was a 
clearly significant univariate and mul tivariate association between phys ical inactivity and 
fibrinogen level (Moller & Kristensen, 1991:344). The THUSA study of Africans in the 
Northwest province of South Africa, found that subjects who reported high physical 
activity (regular exerci se and/or sport, in additi on to wa lking long di stances) had 
significantly lower fibrinogen levels than the moderately active and inactive subjects 
(James ctJJL, 2000:385). Results from the Northern Ireland Health and Activity survey 
supported that physical fitness (measured by using V02 max) has beneficial effect on the 
fibrinogen levels (MacAuley fliJl, 1996:260). 
Therefore it seems that all studies which measu red the rel ationship between long-term 
physical activity and plasma fibrinogen , found that physical fitness is associated with 
lower levels of the protein in the blood. However, less is known about the acute effect of 
physical activity on plasma fibrinogen levels. 
e) Smoking 
The Framingham study found that age-adjusted fibrinogen val ues were significantly 
higher in cigarette smokers than in nonsmokers (see table 4 and 5). Fibrinogen increased 
45 
© Central University of Technology, Free State
with the amount of cigarettes smoked in each sex. Ex-smokers had values as low as non-
smokers did; suggesting a direct but reversible effects (Kannel et oZ. , 1987:1007). 
Table 4 Fibrinogen by cigarette habit: subjects 47-79 years of ageN• 
Cigarettes/day 
None 
< tpack 
> tpack 
il p<o.OOJ 
• p<0.05 
Male (mg/dl) n Female (mg/dl) = 
278 292 
281 296 
301 306 
# Data from the Framminghan study (Kannel e.1.JJL, 1987: 1007) 
Table 5: Age adjusted means offibrinogen by sex alld smoking statusN 
Smoking status Male (mg/dl) Female (mg/dl) 
Nonsmokers 275(n=108) 293(n=371) 
Former smokers 282(n= 109) 290(n= 115) 
Current smokers 296(n=336) 302(n=275) 
ilDijJerences significant at p<O. 00 J for men and p<O. 07 for women 
# Data from the Framminghan study (Kannel et oZ., 1987: 1007) 
A switch from cigarette to cigar smoking is inexplicably associated with a large increase 
in plasma fibrinogen, which is in keeping with the observation that cigar smokers are at 
an increased risk oflHD (Lip, 1995: 160). 
Lip (1995:165) reported numerous study results in a literature review, which showed the 
positive relationship between smoking and plasma fibrinogen levels: 
• The WHO Co-operative trial (15 000 men) of clofibrate found the highest fibrinogen 
levels amongst smokers. 
• Results of the Copenhagen cross-sectional population study, (439 men aged 51 years) 
indicated that one of the strongest independent associations with plasma fibrinogen 
was smoking habit. 
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• A Swedish study of a cohort of 788 healthy men aged 54 years indicated that plasma 
fibrinogen positively correlated with cigarette smoking. 
• The Northwick Park Heart Study found the lifetime duration of smoking was a 
determinant of initial plasma fibrinogen levels. 
There are various possible mechanisms that explain the effect of smoking on the plasma 
fibrinogen levels (Lip, 1995:160): 
• Smoking may lead to endothelial damage, resulting in the stimulation of the 
coagulation system and increased production and release of coagulation factors. 
• Smoking may directly lead to an increase in the concentration of clotting factors, 
resulting in a tendency to thrombosis and the formation of mural micro thrombi on 
otherwise damaged endothelium . 
• Activation of lung macrophages by smoking, which can produce hepatocyte-
stimunlating factor (IL-6), which increases fibrinogen synthesis and secretion. 
Results from the MONICA study (E li asson et aI., 1994: 15) indicated that although 
plasma cotinine concentration (the main metabolite of nicotine) were higher in snuff 
users than in smokers, snuff users had fibrinogen levels lower than smokers, equivalent to 
non-smokers. The conclusion was drawn that the detrimental effect of smoking on 
fibrinogen levels is not mediated by nicotine. A small study of nicotine gum corroborates 
these conclusions (Johnston et aI., 1984: I 03). 
t) Adult height 
Brunner e1..SJ.L (1996: 1009) indicated that taller men (p<0.05) and women (p<0.005) had 
lower fibrinogen concentrations than shorter men and women. This observation is 
intriguing and may be related to socio-economic class and nutritional status in childhood. 
, Shorter men and women may be a consequence of chronic malnutrition (stunting) as 
children. 
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g) Metabolic syndrome 
Fibrinogen concentration shows a direct association with features of the metabolic 
syndrome, including raised fasting insulin concentration, high waist hip ratio, raised 
serum triglycerides, hypertension and low high-density lipoprotein cho lesterol (Brunner 
/lLQL 1996:1011). In the Framingham Study and SHHS diabetic subjects had a higher 
plasma fibrinogen concentration than non-diabetic subj ects (reviewed by Lip, 1995: 159). 
The relationship between fibrinogen and the features of the metabolic syndrome, suggest 
a common aetiology. 
h) Furnace dust exposure 
Long-term inhalation of particles retained 111 the lungs will create chronic low-grade 
inflammation in association with an increase in plasma fibrinogen. 
This confirms the general hypothesis regarding inhaled particle exposure 
(ferromanganese I silicomanganese of furnace workers and manganese-exposed 
Moroccan miners) and the occurrence ofIHD (Sjogren, 1998:236). 
i) Stress 
A cross-sectional study of a occupationally homogeneous group of healthy middle-aged 
males in middle-management positions indicated that chronic work stress in terms of high 
effort and low reward is associated with significantly increased relative risks of having 
abnormal levels of LDL-cholesterol and plasma fibrinogen (Siegrist el al., 
1997:147,154). 
j) Gender 
Comparing men and women, fibrinogen concentration IS substantially higher in 
premenopausal women than in men (Brunner ct.JJ.L 1993:197). The exceptions are 13-14-
year -old Jewish children, the white South African 17-20 year olds, and two groups in the 
French study (4-14 and 40-50 year olds) found in studies reviewed by Vorster 
(1999: 139). 
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A study determining the plasma fibrinogen concentration In Spanish chi ldren and 
adolescents showed higher levels of fibrinogen in girls than in boys, with a more marked 
but reversed difference than in adults (Sanchez-Bayle f.LJ1L, 1993:325). 
k) Age 
In women, fibrinogen shows no relation with age before menopause, but rises with age 
after menopause. The interaction of menopause status and age is such that the difference 
in fibrinogen associated with menopause is close to zero at 45, rising to about 10% at the 
age of 55 . This finding presumably reflects time elapsed since the menopause, rather than 
chronological age (Brunner e.LnL 1993: 197). In men and women fibrinogen increases 
about 0.1-0.2 gil per decade during adulthood (Fo lsom, 1995:21). It is not clear if these 
increases in fibrinogen with age are related to overall health status or to age per se. 
\) Obesity and body mass index (BMI) 
In obese patients (BMI >30 Kglm2) the plasma viscosity and plasma fibrinogen levels are 
significantly increased compared to healthy subjects (BMl <25 Kglm2) (Lip, 1995: 160). 
Bao ~(1993:324) demonstrated in the Bogalusa Heart Study a consistent increase in 
fibrinogen levels with ponderal index and skinfolds in ch ildren. M0 11er & Kristensen 
(199 I :344) found a strong univariate association between the wa ist-to-hip ratio and the 
fibrinogen levels in a study of 439 51-year-old men. 
In the THUSA study of Africans in the Northwest province of South Africa, BMI showed 
a significant positive correlation with plasma fibrinogen leve l(r=0.25; p=O.OOO) (James fl 
IlL, 2000:385). 
Folsom &ill.. (1991:200) developed two models to predict changes in fibrinogen for a 5-
kglm2 increase in BM!. The first model showed a 0.85 gil increase in men and a 1.23g/l 
increase in women, and the second a 0.6 gil increase in men and a 0.98 gil increase in 
women. 
It was therefore assumed that the influence of BMl on fibrinogen levels was greater in 
women. These findings are supported by the results from the second WHO MONICA 
Augsburg Survey (Korobot &JJL, 1992:785). In contrast, Iso tl.1lL (\996:1 \52) found a 
positive association between BMI and fibrinogen in white and Japanese men, but not in 
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Japanese women. Little is known about the effect of weight loss and fibrinogen levels. 
Vorster rl...!JL (1997: 120) indicated that an increase in plasma fibrinogen levels during 
rapid weight loss may be related to the increase in free fatty acids. However, slow weight 
loss is associated with a decrease in fibrinogen levels. 
m) Alcohol consumption 
A decrease in plasma fibrinogen of approximately 0.78% per 109 alcohol consumed has 
been noted (Lip, 1995: 160). 
Lee et al. (1990:915) reported that drinkers had lower fibrinogen levels than non-drinkers 
for both sexes according to the SHHS study. Among males, there was no dose-response, 
, 
but females that claimed to have consumed low quantities of alcohol during the previous 
week had much higher fibrinogen levels than those consuming larger amounts . 
A prediction based on results from the ARIC study and the use of two different models, 
showed that an ethanol intake of 100g per week was associated with 0.22 gil and 0.09g11 
lower plasma fibrinogen levels in men and 1.29g11 and 0.92g/1 lower levels in women 
(Folsom~, 1991: 200). 
n) Hormones 
In the CARDIA study the use of oral contraceptives by women was associated with 
higher fibrinogen levels than in nonusers (Folsom !IDlL. 1993: 1030). In the SHHS it was 
found, however, that women who had been taking oral contraceptives had lower plasma 
fibrinogen levels compared to the women who had no history of taking oral 
contraceptives (Lip, 1995:159). Karpanon et aI., (1992:354) showed a decrease in plasma 
fibrinogen levels from the ovulatory phase to the follicular phase in hypertensive women 
(from 2.92 to 2.72 gil) and an increase in normotensive controls (from 2.22 to 2.47 gil; p, 
0.0008). Brunner eL.JJL (1993: 197) found that fibrinogen levels of post-menopausal 
women are higher than the fibrinogen levels of pre-menopausal women. Pregnancy is 
sometimes labeled as a "physiological model of hyperfibrinogenaemia", but is 
accompanied by a compensatory rise in fibrinolytic potential (Yin !:.1....JJl., 1998:235). It 
seems that the effect of female sex hormones on fibrinogen levels has been studied in 
some detail. Very little about the effects of other hormones is avai lab Ie. 
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0) Hyperlipidaemia 
The Leigh Study indicated that the incidence of myocardial infarction (MI) was six times 
greater in subjects with raised plasma fibrinogen (>3.5 gi l) and raised cholesterol levels 
(> 6.2mmol/l), when compared to those with low fibrinogen and low cholesterol levels 
(Lip, 1995: 160). In the Bogalusa Heart Study, a positive association of plasma fibrinogen 
with VLDL cholesterol and LDL cholesterol and a negative association with HDL 
cholesterol were found (Bao ~, 1993:324). It is also believed that higher plasma 
fibrinogen level fo r familial hypercholestro laemic female patients than in male patients 
(Jerling tl.QL 1997 :95). 
Results from the THUSA study of Africans in the Northwest province of South Africa, 
showed that a small but significant positive correlation's exist between serum cholesterol, 
,---:: LDL cholesterol and, in women, triglycerides with plasma fibrinogen (James ~ OOK l~ 
2000:391). \, HE prOPF..Rl 
,.. c: T\.lf: 
2 4 NOV ZGC3 
p) Chronic inflammation N 1l-l.ll.ill V 
Fibrinogen is an acute phase protein: Elevated plasma fibrinogen levels f ave- b en - STATE 
indicated in the presence of an even bland chronic inflammation, which is the most 
common concept for the pathophysiology of atherosclerosis (Resch & Ernst, 1994:171). 
Persons with rheumatic disease have elevated fibrinogen levels due to the acute phase 
reaction (Folsom, 1995:22). Chronic inflammatory gingival and periodontal infection is 
also associated with MI, increased plasma fibrinogen and white cell counts (reviewed by 
Lip, 1995:161). 
q) Genetic factors 
Several recent studies support the notion of genetic influence on plasma fibrinogen levels, 
but also reflect controversies: 
• A small but significant 1I1crease 111 fibrinogen level was associated with the rare 
cutting sites of haelII and HindlIl, Bcll and Taq!. At all polymorhic sites 
homozygosity for frequent alleles was associated with about 0.2g11 lower plasma 
fibrinogen leve ls than the heterozogosity at the respective sites (Vasse e/ aI., 
1996:332). 
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• Thomas ~ (1996: 186) indicated an interaction between smoking, age and the 
allele frequency of the G/A-455 polymorphism of the B~ fibrinogen gene and plasma 
levels. 
• Carter ~ (1996:1266) reported that a G/A-455 polymorphism is related to the 
development of CHD in diabetic patients, without influencing the plasma fibrinogen 
levels. 
• Van der Bom !:L11L (1998:623) found that subjects with one or two A alleles had 
significantly higher fibrinogen levels than those with the G/G genotype; this 
polymorphism did not influence the MI risk. 
• In contrast, Yu!:L11L (1996:156) showed that the G/G genotype was an independent 
predictor of MI in a co-dominant manner. 
• Kessler et at. (1997:2882) found that the A/A genotype was more common in patients 
with large vessel disease. A similar pattern has been reported by Iacoviello IfL1lL 
(1998 :265) for the Bell polymorphism. 
It seems that individuals with the rearest genotype (B2/B2) have a 15-20% higher 
fibrinogen level than those with B liB I genotype, and that this po lymorphism could be 
associated with peripheral arterial disease, the severity of CHD, and familial Ml. There 
are indications that the effects of this po lymorphism are smaller in women than in men 
(Iacoviello f1.QL 1998 :266). 
r) Birth weight 
Low birth weight is associated with higher fibrinogen levels in adults. It is hypothesized 
that intra-uterine growth retardation may contribute to the determination of an 
individual's fibrinogen concentration in later life (Barker, 1993: 105). It is believed that 
the effect of infant's weight on fibrinogen is only significant in men (Henry !ILJJL 
1997:556). However, data on this phenomenon is scarce. In the light of childhood 
malnutrition and later risk of chronic di seases, more research is needed in this area. 
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s) Ethnicity 
Across populations, plasma fibrinogen concentration seems to co-vary with the 
population level of IHD. Fibrinogen levels are low among Asians, intermediate among 
English, Gzechs and North American whites, highest among Finns, Scots, African 
Americans and some American Indian tribes. Gambians who are presumably at low risk 
of CVD, have been found to have high fibrinogen levels, a finding attributed to parasitic 
infection (Folsom, 1995:21 ). 
Table 6: Sex, race, and age-specific mean plasma fibrinogen levels (mg/dl) and 
percentage a/participants with fibrinogen levels >350mg/dl # 
Age Men \Vomen 
Wbites (n-I .04i2) Blucks (n=89 I) WlJites (n=U23) Blocks (n=1.I37) 
Mun SD % ;:::350 Mean SD %;?:350 Mean SD % ~350 Mean SD %~3S0 
<30 238 44 2 246 48 4 263 52 5 287 59 13 
;,30 244 50 3 254 49 3 267 58 8 295 63 14 
# Data from the CARDIA study, 1990-1 991 (Folsom USiL, 1993: 1027). 
As Table 6 shows, mean fibrinogen levels were higher (p<O.OOI ) in those aged 30 years 
or more than in those aged less than 30 years, in women than in men, and in blacks than 
in whites (Folsom el al., 1993:1027) . 
In the Bogalusa Heart Study fibrinogen values did not differ essentially between Blacks 
and Caucasians or males and females, although an increase in level s with age or sexual 
maturation was noted in black females (Bao ~1993:324). The authors suggested an 
increase earlier or to a greater extent for black females , which resulted in the highest 
adulthood levels seen in black females. Iso et al. (1989:930) indicated that regardless of 
smoking status, fibrinogen level in Caucasians was higher than in urban or rural Japanese. 
t) Blood pressure 
In the Bogalusa Heart Study, (BaD et al.. 1993:324) a positive association of fibrinogen 
levels with blood pressure in children was found. A number of other studies reported 
significant positive correlation 's of plasma fibrinogen levels with systolic and diastolic 
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blood pressure, but only in women (reviewed by Vorster f1..JJL, 1998: 174; Ishikawa.n...aL, 
1997:891). 
u) Microalbuminuria 
A number of studies have reported that microalbuminuria, 111 both normal and diabetic 
individuals, is associated with CVD. It was reported that those with microalbuminuria 
had higher levels of plasma fibrinogen (Folsom, 1995:24). 
Table 7: Summary of factors associated with plasma fibrinogen concentration 
Positive association No Negative association 
associa (ion 
Strong Modest Modest Strong 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Age 0 Winter 0 Dietary fat 0 Alcohol intake 0 Social class 
Female gender 0 Ethnicity 0 Nicotine gum 0 Physical activity 0 Education level 
Cigarette smoking 0 Blood pressure 0 Fish oil 0 Estrogen replacement 
Inflammatory condition 0 Lipoproteins 0 \·1DL cholesterol 0 Birth weight 
Stress 0 Homocysteine 0 Ethnicity 
Obesily 0 Serum insulin 
Diabetes 0 Microalbuminuria 
Menopause 
Oral contraceptives 
Leucocyte count 
As table 7 shows, the association between the factors influencing plasma fibrinogen 
levels varies from strong to modest. Association can either be positive or negative. 
2.2.8 Fibrinogen status: normal ranges 
Fibrinogen plasma levels of 1.5-4.5 gil are considered norma l. This concentration far 
exceeds the minimum concentration of 0.5-1 gil necessary for normal haemostasis. The 
upper limit of 4.5 gi l is also considered normal but refers to fibrinogen as an acute phase 
protein. In the absence of an acute inflammatory disease, levels exceeding roughly 3 gil 
have shown to be associated with an increased risk for cardiovascular events (Resch & 
Ernst, 1994:170 and Lip, 1995:155). As a response to stimuli such as acute inflammatory 
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processes, plasma fibrinogen levels may easily double within days and usually normalise 
almost as fast when the pathological stimulus is no longer present (Resch & Ernst, 
1994:170). 
The plasma fibrinogen levels (gil) of HIV negative African men and women stratified for 
age and level of urbanisation found in the THUSA study are indicated in Table8. Age 
showed a significantly positive (p=0.001) correlation with plasma fibrinogen of men 
(r=0.14) and women (r=0.11) (James e/ ai. , 2000:386). 
Table 8: The plasma fibrinogen levels (gil) of HIV negative African men and 
women stratified for age and level of urbanisation found in the THUSA study. # 
Gender Level of urbanisation 
,and age 
group 
Men n= 81 82 83 84 85 TOTAL 
Mean SD Mean SD MeaD 81) Mean SoD Mean SO Mean SO 
15-25 169 2.56 0.53 3.14 0.69 3.01 1.19 2.97 1.19 3.14 0.80 2.9S "·b,c 0.92 
25-35 148 2.74 0.84 3.44 0.62 3.25 1.58 2.91 1.J5 3.3 1 0.94 3. 11 ~ 1.10 
35-45 111 2.91 0.93 3.63 0.77 3.70 1.23 2.96 0.90 3.64 1.03 3.24"e 1.01 
45-55 112 3.28 1.16 3.76 0.79 3. 13 1.39 2.95 1.01 3.19 0.83 3.23' 1.09 
55-65 75 3.38 1.21 3.83 0.47 3.33 1.17 4.03 2.02 2.69 1.67 3.55c.d,c 1.37 
65+ 39 2.87 1.07 5.20 3.92 4.52 1.38 3.17 0.84 
- -
3.21 1.32 
Women 
15-25 171 2.91 0.66 3.42 0.78 3.78 1.78 3.80 1.55 3.64 0.88 3.24' 1.16 
25-35 226 3. 11 0.91 3.58 0.78 3.92 1.35 3.67 1.03 3.90 1.05 3.38b 1.10 
35-45 201 3.38 0.87 3.76 0.85 3.69 1.25 3.84 1.04 3.97 0.81 3.54 1.01 
45-55 157 3.39 0.91 3.79 0.87 3.87 1.32 3.93 1.47 3.57 1.34 3.49 1.15 
55-65 93 3.76 0.92 4.01 1.19 3.61 1.05 3.96 1.27 3.89 - 3.7p·b 1.23 
65+ 37 3.29 0.8 3.24 0.37 3.06 0.18 3. 85 1.36 - - 3.37 1.22 
AbbreVlOllOns: S f - rural; S2-I arms; S3 =mformal h OUSing areas (squatter camps); S4 - urban (middle 
class); S5=urban professional . 
•.•. , .... The same symbol differs significantly (p<O.05) within gender between age groups 
• James e/ al., (2000:386) reported values obtained from the THUSA study. 
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Results obtained in the BRlSK study in the Cape Penisula, South Africa, are given in 
Table 9. Mean fibrinogen of men and women were higber than published data for 
Europeans but slightly lower than values for African Americans. Women aged 45-54 
years had the highest level (3.l3 ± 0.89g11) and men aged 15-24 years had the lowest 
(2.13 ± 0.88 gil). Fifteen per cent of men and twelve per cent of the women had a level 
greater than one SD of the mean for their age group (Vorster e1...iJl., 1998: 171). 
Table 9: Plasmajibrinogen values obtained in the BRISK studl 
Men 
Age 0 
Mean SD 
15·24 120 2.31 0.88 
25·34 84 2.42 0.88 
35·44 68 2.58 1.03 
45·54 45 2.72 1.04 
55-64 35 2.63 0.59 
Women 
15-25 lSI 2.62 0.88 
25-35 116 2.78 0.77 
35-45 85 2.70 0.82 
45-55 54 3.13 0.89 
55-65 41 3.07 0.99 
• A study of Africans In the Cape PenInsula South Afnca (Vorster&.aL, 1998.171). 
2.2.9 Modifyin2 fibrino2en levels 
If one accepts the hypothesis that elevated plasma fibrinogen levels are causally linked to 
atherogenesis and to its thromboembolic complications, lowering the fibrinogen levels 
should retard the artherosclerotic process and reduce cardiovascular events (Koenig, 
1995 :56). As discussed above plasma fibrinogen levels are regulated by an interesting 
and complex interplay between environmental and genetic factors (De Maat, 2001 :509). 
Factors proven to have a lowering effect on plasma fibrinogen are: 
• Fibric acid derivatives such as bezafibrate (but not gemfibrozil) lower plasma 
fibrinogen levels up to 20% or more. These agents also modify lipid levels in a 
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beneficial direction. Agents lowering fibrinogen levels selectively are under 
development (Meade, 1995:33). 
• Dietary supplementation of healthy young men and women with fish oil capsules, by 
using olive oil as a placebo, lowered plasma fibrinogen in women who had relatively 
high baseline values and not in men, who had lower base line values (Oosthuizen et 
IlL, 1994:560). 
Therefore, it seems that optimal nutritional status (or balanced diet); long term weight 
loss, not smoking and physical activity are the lifestyle interventions that would lower 
plasma fibrinogen. These interventions wi II also have beneficial effects on other CHD 
and CVD risk factors. 
2.3 Vitamin A 
2.3.1 Characteristics of vitamin A 
Vitamin A, with the common name retinol, occurs in nature mainly as fatty acid esters. 
They are polyunsaturated, making them susceptible to destruction by oxidation. Vitamin 
A is generally organised in two groups: 
• Retinoids - exist as retinol, retinyl esters, retinal and retinoic acid (preformed vitamin 
A) (see figure 5) 
• Carotenoids - include n, ~, y, carotene and cryptoxanthin. B-carotene are the most 
important form (see figure 5). 
(Reviewed by: Weigley et aI., 1997: 168; Williams, 1993: 171; Bohman et al., 1982:251) 
2.3.2 Function of vitamin A 
Vitamin A is essential to the numerous metabolic processes of the human body (Bohman 
etal.,1998:251). 
a) Growth 
Vitamin A plays an essential role during cell differentiation. Therefore, vitamin A is 
involved in reproduction, growth, bone and tooth development, synthesis and 
maintenance of healthy ep ithelia, maintenance of the skin and mucous membranes 
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(Klemm & Ross, 1999:45; Department of Health, 1998:5; Stoltzfus & Klemm, 1997:58; 
Weigley et ai., 1997:1 68). 
b) Immunological functions 
Vitamin A is essential in the functioning of the immunological system . It has been proven 
that the immune reaction of children with vitamin A deficiency (V AD) could be 
enhanced by means of improving their v itamin A status. Which leads to a reduction in 
prevalence of illness from infectious diseases and in mortality (Department of Health, 
1998:5; Stoltzfus & Klemm, 1997:58; Sommer, 1997:4). 
c) Vision 
The most commonly recognised function of vitamin A is its role in vision. Rhodopsin, a 
protein containing vitamin A, is the eye pigment sensitive to light. When light shines on 
rhodopsin, it splits into ops in and retinal. Some vitamin A is lost in this process. In the 
dark, opsin and retinal rapidly recombine (provided there is enough vitamin A). 
Insufficient vitamin A leads to slow regeneration and the eye cannol adapt to changes in 
light (condition called "night blindness") (Klemm & Ross, 1999:44; Weigley e1....JJl. , 
1997: 169). 
d) Antioxidant 
An antioxidant is a natural or synthetic compound that is itself oxidised readily, thus 
preventing other compounds from being ox idised. Vitamin A and ~-carotene are dietary 
antioxidants, thought to playa major role in preventing oxidative damage in body cells. 
Other oxidants include Vitamin D and E (Weigley et ai., 1997: 164-1 .65) 
2.3.3 Dietarv sources of vitamin A 
Several sources (Weigley et ai., 1997: 169; Department of Health, 1998:7; Mutare city 
Health Department, 1997:3) mention that pre-formed vitamin A is only contained in 
animal foods: egg yolks, liver and kidneys, dairy products such as butter, margarine, 
yellow cheese, whole-milk cheeses, cream, whole milk, and cod liver oi l. The precursors 
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of vitamin A, u- and ~-carotene and other carotenoids are mainly present in green leafy 
and red vegetables and in dark yellow and orange fruits and vegetables. 
2.3.4 Metabolism of vitamin A 
Retinol is freed in the gastrointestinal tract, transported across the intestinal cells and 
estrified to retinyl esters (Neal, 1998:4). Vitamin A, either as pre-formed retinol and its 
esters or as pro-vitamin A carotenoids, is absorbed in the upper part of the small intestine. 
In chylomicrons it passes through the lymphatics into the systemic circulation, where it is 
bound to lipoprotein. Vitamin A is stored in the liver and on request retinyl esters in the 
liver are hydrolised to free retinol (Neal, 1998:4). When vitamin A is released from the 
liver it binds to specific proteins, retinol-binding protein (RBP) and transthyretin (TIR) 
(Weigley et al. , 1997: 170; Williams, 1993 : 173). 
Figure 5: 
R = H - all-tl'Bns-retlnol 
(al I-trans-Vltam InA) 
OR 
,0 
R = CH3 - C retlny' acetate 
......... 
13-cls-retlnol 
B-carotene (a provatamln A) 
OH 
Vitamin A molecular composition adapted from Bohman et al., 
1982:251. 
59 
© Central University of Technology, Free State
2.3.5 Dietary vitamin A requirements 
The amount of vitamin A in food is commonly expressed in International Units (IU) or 
retinol equivalents (RE) (Weigley &.iJI. , 1997:168; Williams, 1993:179 Department of 
Health, 1998:10). RE is a unit that was developed to standardise the measurements of 
available vitamin A activity of different vitamin A sources: 
IRE = 3.33IU vitamin A activity from retinol 
IRE = Iflg retinol or 6 flg ~-carotene. 
Table10 Recommended daily allowance for vitamin A 
Category (Age) Weight (kg) Height (em) 
Infants 0-6 months 6 60 
6-12 months 9 71 
Children 1-3 years 13 90 
4-6 years 20 112 
7-10 years 28 132 
Males 11-14 years 45 157 
15-18 years 66 176 
19-24 years 12 177 
25-50 years 79 176 
51+ years 77 173 
Females 11-14 years 46 157 
15-18 years 55 163 
19-24 years 58 164 
25-50 years 63 163 
51+ years 65 160 
Pregnant 
Lactating first 6 months 
Lactating second 6 
months 
Vitamin A (RE) 
375 
375 
400 
500 
700 
1000 
1000 
1000 
1000 
1000 
800 
800 
800 
800 
800 
800 
1300 
1200 
As descrzbed by Welgley et al., 1997:168-169; Mahan & Escot-Stump, 2000:70 
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2.3.6 Vitamin A Status 
Vitamin A status, on the basis of serum vitamin A concentration, was classified by the 
World Health Organisation (WHO) as follows: 
Plasma retinol Description of status 
Le.ss than 10 f!g/dL YAD 
10-19,9 flg/mL low (marginal vitamin A status) 
20-29,9 flg/dL adequate status 
More than 30 flg/dL normal, well-nourished status 
(UNICEF & WHO, 1994:15). 
2.3.7 Vitamin A deficiency 
Vitamin A is a powerful child survival tool, reducing child mortality by 23-24 (Malanick, 
1999:1 ; Humphrey, 1998:S2). VAD as a public health problem occurs within an 
ambience of ecological, economical and social deprivations in the macroenvironment in 
which populations are found , as well as the microenvironment where families live. The 
individual environment and malnutrition can take a variety of forms that contribute to 
each other, such as deficiencies of micronutrients that include iodine, iron and vitamin A, 
and protein energy malnutrition (Bellamy, 1998: I; WHO, 1995:5). 
Globally, vitamin A is a major problem in 75 countries. In developing countries, 125-190 
million children of preschool age are at risk ofYAD. Five to 10 million of these children 
will develop xerophtalmia, and every year about 500 000 of these children will lose their 
sight. These conditions can lead to 1-2.5 million child deaths annually (Bellamy, 1998:2; 
Humphrey, 1998:S2; Department of Health, 1998:3) 
In 1994 the SAYACG study determined that one in three children, under the age of six 
years had a marginal vitamin A status. Only one percent of children had a serum retinol 
level of higher than 50flg/dL. The prevalence ofYAD in children was found to be higher 
in rural areas (38%) compared to urban areas (25%) (Labadarios, 1999:5; Department of 
Health, 1998:3; SA YACG, 1995:4; Department of Health, 1999: 12). 
In addition to young children in South A [rica, it is suspected that adolescents and 
especially women of child bearing age may also be vitamin A deficient. In a meta-
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analysis of dietary intakes, Vorster !4JJ1.. (1997: 1 09) showed that urban black females 
aged 16-24 years, vitamin A intake were 56.5% ofRDA. 
2.3.8 Intervention strategies 
Elimination of VAD as a public health problem should be a principle element of child-
and maternal survival programmes (Sommer, 1997:3). It is important that any 
recommended strategy should be implemented in conjunction with other public health 
measures, such as oral rehydration programmess, control of intestinal parasitic disease, 
prevention and treatment of infections and promotion of breast feeding (SA V ACG, 
1995:19, 144; Department of Health, 1998:17). 
A multi-sectorial alliance, called the vitamin A initiative (VITA), was combined by the 
USAID, comprising of private sector, non-governmental organisations, private voluntary 
organisation and civic organisations (Malanick, 1999: 1 ). VITA launched a multi strategy 
plan in order to reduce V AD. Strategies included supplementation, fortification and 
diversification of food (Malanick, 1999: 1). 
a) Supplementation 
Vitamin A supplementation is a low-cost, reliable and effective way of combating VAD, 
and can be rapidly implemented as a programme strategy on a national scale (USAID, 
1993:8; Sommer, 1998:3). 
Based on the SA VACG report (1995:8-10), a supplementation programme for South 
Africa was recommended: 
• A national vitamin A capsule distribution programme. Distribution to be started in 
provinces at highest risks, for a period of three years, for all children 6-71 months of 
age; 
• All children arriving at health centers presenting with malnutrition, measles or 
diarrhea, should receive a high dose vitamin A supplementation; 
• Children under the age of 2 years should be the targets of nutritional intervention and 
their mothers for nutritional education. 
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b) Fortification 
Food fortification, more than any other technology available today, offers an affordable 
and immediate opportunity to improve lives and accelerates socioeconomic development. 
Food fortification has been responsible for eradicating most of the vitamin and mineral 
deficiencies in developed countries (Anon., 1997a: 12). 
Table 11: Tested strategies for vitamin A food fortification 
. 
I' ,COUl\tFY Food fortification program Date 
Denmark V A fortified margarine 1918 
Canada Milk fortified with vitamin A 1945 
Guatemala Vitamin A fortified sugar 1970 
USA Vitamin A and Vitamin D to fluid milk 1984 
Philippines Exploring of vitamin A fortified monosodium 1985 
glutamate - not implemented 
Bangladesh VA fortified wheat 1986 
Philippines V A fortified wheat 1993 
Andes of Peru Fortified school breakfast 1993 
Thailand Instant noodles fortified with vitamin A. iron and 1994 
iodine 
Mexico Chocolate powder drink fortified with vitamin A, iron 1994 
and iodine 
Indonesia Vitamin A fortified rice 1994-1996 
Japan Rice with vitamin A and B-vitamins 1999 
Adaptedfrom Lofti, 1997:7; Murphy, 1996:69 
c) Food diversification 
Food diversification is a long-term intervention strategy that includes approaches to 
change behavior in order to improve consumption of vitamin A rich foods. This can be 
achieved through communication, social marketing and nutrition education, home food 
provisioning through activities such as home gardening, and technological developments 
regarding food and nutrient preservation. 
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d) Br;east-feeding 
Breast-feeding is known to substantially reduce the risk of V AD, a protective effect, 
which can extend to the third year of life (Department of Health, 1998: 17; SAVACG, 
1995:19,144). 
2.4 Fortification of foods with vitamin A 
Fortification could be described as the addition of nutrients at levels higher than those 
found or never found in original food (Weigley et ai., 1997:29). Another definition 
describes fortification as the addition of one or more nutrients to food, whether or not it is 
normally contained in that specific food, in order to prevent or correct a demonstrated 
deficiency (Brady et ai., 1996: 12). 
For a programme to be effective it is necessary that the fortified food (fortification 
vehicle) must reach the target population (Fitzgerald, 1997: I). To ensure that the most 
vulnerable members of the population benefit from the fortification process, a staple food 
must be used as vehicle (Anon., 1997a:12). 
At the International vitamin A Consultative Group (IV ACG) meeting 1996, it was 
reported that the average sugar consumption per person per day in SA is 100g (Nalubola 
& Nestel, 1999:100). The THUSA study reported an average of35-60 g per adult per day 
in the North West Province of SA (Macintyre, 1998:258). Studies indicated that 93% of 
the families in SA consume sugar (Hendricks, 1999:4). It can therefore be assumed that 
sugar is a suitable vehicle for fortification with vitamin A, in the combating of V AD. 
2.5 Hypothesis of this study 
The hypothesis tested in this study states that the consumption of vitamin A fortified 
sugar by a randomly selected group of young (13-25 year old) African girls, a group 
known to have a raised plasma fibrinogen level, will improve vitamin A nutritional status 
and decrease risk for future stroke or CVD by decreasing plasma fibrinogen levels, 
regardless of their initial vitamin A status. 
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The theoretical basis and known scientific evidence, on which this hypothesis rests, wi II be 
discussed briefly. 
2.5.1 Vitamin A and fibrinogen 
The relationship between nutrition and plasma coagulation factors, especially fibrinogen, 
is far from clear. In Table 12 the results of a few studies which examined these 
relationships are summarised. 
It was mentioned in 2.2.7(s) that there is evidence that black South Africans have higher 
plasma fibrinogen levels than comparable subjects from the other population groups. The 
causes of these higher levels are not known, but it has been speculated that the high 
plasma fibrinogen contributes to the high stroke rate in South African blacks (Vorster g1 
ill., \998:169). It is therefore important to examine if vitamin A supplementation of the 
diet of black South Africans may have beneficial effects on their plasma fibrinogen -
based on the suggestions in the literature that there may be an interaction between 
vitamin A status and levels of fibrinogen. 
Table 12: 
Researchers 
Relationship between vitamin A and coagulation factors as proved by 
research studies 
Sample population Findings Reference 
Van Giezen, Boon, Rats Retinoic acid increased fibrinolysis by selectively Van Giezen eLiIl., 1993 :384. 
Jansen & Bouma (1993) increasing tPA 
Van Bennekum, Emeis, Vitamin A deficient rats Retinoic acid increased fibrinolysis Van Bennekum eL_aL, 
Kooistra & Hendricks I 993:R936. 
(1993) 
Kruger. Vomer, Venter Healthy elderly women Subjects with higher levels of vitamin A and SRBP Kruger eL.al., 1994: 11 3. 
& Viljo,n (1994) had significantly lower fibrinogen levels with 
simultaneous intake of micronutrient supplements. 
Eliasson, Asplund , MONICA study - humans High plasma retinol levels were associated with Eliasson f1..11L , 1995:90. 
Evrin, Huhtasaari & lower plasma fibrinogen levels, but also with low 
Johansson (1995) tPA and high PAI-I levels, thus with impaired 
fibrinolytic activity 
Hankey, Rumley, Ha, Patients with angina Positive associations between plasma retinol HankeyfLal.. 1996: 193. 
Lowe & Lean (1996) concentration standardised for total plasma lipids 
and PAl-l activity and factor VIle 
James eLaL(2000) Africans in transition Low nutritional status in men and obesity in James e.t.aL2000:390 
women were associated with high plasma 
fibrinogen 
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2.5.2 The hypothesis 
The hypothesis developed for this study, namely that increased vitamin A intake through 
conswnption of vitamin A fortified sugar, will decrease plasma fibrinogen levels of a 
group of black South African women, is based on the evidence that there is a possible 
interaction between vitamin A and plasma fibrinogen. As indicated in figure 6, 
individuals with a low vitamin A status will , due to the stressful or stannous influence of 
V AD and under nutrition on the body as a reactive condition, have an increased plasma 
fibrinogen level. Increased plasma fibrinogen levels increase the risk for cardiovascular 
disease. 
Figure 6 
VITAMIN A 
STATUS 
..0.. Vitamin A U (Mcronutrient 
deficiency 
addressed) 
? 
• 
• 
.,[} Fibrinogen 
..ij.. risk CIi), stroke 
Associa tions between vitamin A and fibrinogen status and suggested consequences of 
increased intakes of vitamin A 
Hypothesis 
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CHAPTER 3 
STUDY DESIGN AND METHODS 
3.1 Introduction 
If one accepts the hypothesis that elevated plasma fibrinogen levels are causally linked to 
atherogenesis and to its thromboembolic complications, lowering fibrinogen levels 
should retard the atherosclerotic process and reduce cardiovascular events, which is of 
considerable clinical and public health interest. 
The THUSA project in the North West Province found that the average daily sugar 
consumption of adult Africans between 15-65 years was between 35 and 60 grams. 
Based on these findings, it was decided to use vitamin A fortified sugar in this project to 
examine relationships between vitamin A and plasma fibrinogen. The objective was to 
ensure that vitamin A needs were met in the target population, without resulting in 
excessive intakes. It was decided that 15 micrograms (flg) of vitamin A per gram sugar 
will both satisfy needs and remain below the maximum acceptable limit (OMNI, 1996: I) 
if up to 100 g fortified sugar is consumed daily. Therefore, participating subjects in this 
study were requested to consume 60 g of sugar daily, providing 800 flg vitamin A. 
This study form part of a clinical intervention trial that evaluated the fortification of sugar 
with vitamin A. Dr. Wilna Oldewage-Theron co-ordinated and administrated the project 
as project leader. This project formed part of Dr. Wilna Oldewage-Theron PhD. study. 
Emsie Dicks studied the compliance and consumer acceptability of the fortified sugar. 
Mosa Selepe did the nutritional data gathering and analyses. Jose van Rensburg assisted in 
blood analysis. The researcher of this thesis was responsible for standardising laboratory 
infrastructure, training the nursing sister for fieldwork, and managing the laboratory test 
procedures and quality control program. 
The researcher also co-ordinated consigns of the vitamin A samples. 
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3.2 Ethical Considerations 
Both the Ethics Committees of Potchefstroom University for Christian Higher Education 
(CHE) and the Vaal Triangle Technikon approved the study. The protocol was submitted 
in accordance with the existing policy for research in both institutions (Annexure I). 
Written parental or guardian consent for drawing of blood for subjects younger than 21 
years of age were obtained. All the subjects older than 21 years signed the voluntary 
informed consent form prior to the inclusion of the subject in the study. The consent 
form included information explaining the purpose of the study as well as the procedures 
to be followed during the study (Annexure 2). 
3.3 Study design 
Randomly selected subjects were "blinded" and received anonymous intervention. They 
knew that sugar was the intervention product, but did not know what it contained. The 
vitamin A fortified sugar was indistinguishable from the non-fortified sugar (placebo), 
and was packed in identical quantities of 5 kg purple bags. The sugar was issued to the 
participants every four weeks for a period of 12 weeks after double baseline 
measurements and blood samples were taken. The researchers who took measurements 
and analysed blood samples were also blinded to the intervention. The study was 
therefore a double blind, placebo-controlled parallel study. 
See figure 7 for a schematic presentation of the study design 
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3.4 Fortification of sU2ar 
Fortification of sugar as discussed In the thesis of Dr. W.H. Oldewage-Theron 
(Oldewage-Theron, 2001). 
3.4.1 Procurement of vitamin A fortified sU2ar 
Roche Vitamins and Fine Chemicals (Pty) Ltd in Isando, South Africa agreed to fortify 
the sugar with vitamin A during February and March 2000. The sugar used for this 
research project was Selati® white sugar (l2,5kg bags). The same brand of sugar was 
used throughout the project for both the fortified and non-fortified product. The reason 
for using the same brand of sugar was to ensure uniformity in quality, crystal size and 
colour (also determined by crystal size) of the sugar. 
3.4.2 Fortification levels 
The concentration level of fortificant added to sugar is critical. The underlying objective 
was to have effective, but safe fortification. The information required to determine the level 
of vitamin A added to sugar for this project included: 
Preparation of the vitamin A premix was based on 100 % RDA for females l3 to 25 years 
which is 800f.1g RE/day (4000 IU), and an average consumption level of 60g of sugar per 
day. The recommended level of fortification included an average of about 20 % to cancel 
possible loss due to processing and storage. Vitamin A concentration in the premix was 
80000 IU/g sugar (24,Omg RE/g) and was mixed to refined sugar at a ratio of 1:1000 to give 
80 IU/g sugar (24,0f.1g RE/g). 
3.4.3 Fortification technolo2Y 
Fortifying sugar with vitamin A included the preparation of a premix and the addition of 
premix to sugar (Arroyave & Dary, 1996: 13). This process is facilitated by diluting retinyl 
palmitate (form of vitamin A used in sugar fortification) (containing 75000 f.1g/g (250 000 
IU/g), in a small amount of sugar to form a premix (Anon., 1997: 1; Arroyave & Dary, 1996: 
6). A vegetable oil, low in peroxides and low in unsaturated fat, adheres the vitamin A 
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beadlet to the sugar crystal (Figure 6). An antioxidant (Ronoxan-A) blended from natural 
antioxidants, for example, ascorbyl palmitate (250 mg/g), DL-alpha tocopherol (50 mg/g) or 
lecithin (700 mg/g), prevents the oil from rancidness. The antioxidant also prevents the 
development of adverse sensory characteristics of sugar. 
The vitamin A levels of the different batches of fortified sugar were analysed and verified 
by Roche Products (Pty.) Ltd. (Annexure 3). 
Figure 8 Electronmicrograph indicating vitamin A beadlets 
adhered to the sugar crystal (Anon., 1997:2; Mora & 
Dary, 1995:1) 
3.4.4 Packaging of fortified sugar 
The fortified sugar was packed in plastic bags, where after it was placed into strong 
carton boxes. The label on the boxes included the manufacturing date and weight (25 kg) 
of each batch. The sugar was transported to the Vaal Triangle Technikon. The sugar was 
repacked two days before distribution every fortnight . Strong ultraviolet (UV) resistant 
purple coded plastic bags, each containing Skg of sugar were used. 
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3.4.5 Instructions 
Written instructions were compiled to ensure that the sugar would be used and stored 
correctly (Annexure 4). Every time the sugar was distributed, each subject received an 
information leaflet. The aim of the leaflet was to ensure that the subjects would use the 
sugar according to the provided instructions discussed in the nutrition education program 
and to encourage other household members to use the given sugar. 
3.5 Trainin2 of fieldworkers and protocol of procedures 
• Ten fieldworkers were recruited from the postgraduate Vaal Triangle Tehnikon 
students in Food and Nutrition and Food Service Management. All were Sotho 
speaking women. From the onset of this project, extensive training was incorporated. 
Both training for the initial implementation of the activities and refresher courses 
throughout the project were included. The fieldworkers received detailed instructions 
regarding anthropometric measurements and administering the qualitative food 
frequency questionnaire. Emphasis was placed on ensuring that the fieldworkers 
were aware of the objectives and importance of the projcct. In addition Lo the initial 
training sessions, fieldworker manuals were prepared and printed in English 
(Annexure 5). All fieldworkers throughout the clinical intervention trial used the 
instruction manuals. The purpose of the manual was to ensure standardisation and 
uniform procedures. (The manual and training was facilitated by W Oldewage-
Theron). 
• A qualified nursing sister was incorporated in the fieldworker's team. The nursing 
sister received a fieldworkers manual , was trained by the researcher in the expected 
sampling procedure as well as sample handling. 
• The group of researchers developed a fieldwork administration form (Annexure 6). 
The form was utilised to check the attendance of each subject at each activity point 
(station) during the intervention trial. The activities were numerically numbered and 
were: 
.:. Station 1: Recruitment of subjects and handing in of completed forms 
.:. Station 2: Anthropometry 
.:. Station 3: Handout and/or completion of the different questionnaires 
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.:. Station 4: Clinical signs and collection of blood samples 
.:. Station 5: Snacks handed out 
.:. Station 6: Nutrition education programme 
.:. Station 7: Issuing of the sugar 
3.6 Sampling strategy 
3.6.1 Power calculations 
Florey (1993: 1882) indicated that power calculations are necessary in determining the 
likeness to detect an effect for a given sample size, effect size and level of significance. 
The variable used in the power calculation was plasma fibrinogen concentration because 
the main objective of this study was to examine the effect of dietary vitamin A 
fortification on fibrinogen levels. The sample population, however, varied from the 
calculated value to accommodate the calculated sample size for other parameters used in 
the study (ex. Soluble transferrin receptor n=88). 
To calculate the sample size, the means of the continuously distributed variable, 
fibrinogen, the baseline difference between the means of the experimental- and placebo 
groups (d), the likely standard deviation (s) of the variable (same for both groups) and the 
selected values for significance (a) and power (13), were used. 
For this study 95 % significance and 90 % power was chosen and the formula for sample 
size (n) was thus: 
The sample size is for each group, experimental and placebo and the total number of 
subjects in the study must thus be 2n (Florey, 1993: 1183-1184). 
Ho Vitamin A fortified sugar (80 IV per gram) consumption will not 
decrease fibrinogen levels by 0,5 mg/L. 
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Vitamin A fortified sugar (80 IU per gram) consumption will 
decrease fibrinogen levels by 0,5' mg/L. 
n = 2 (l,96+1 ,28i 0,42/0,52 
13 
Based on the power calculation, it was decided to include 44 subjects per treatment 
group, A scaling-up factor was built into the sampling procedure to provide for dropouts, 
In the end 50 subjects per treatment group were selected to participate in the study, 
Usually an experiment should be just long enough to allow for the effect of exposure 
change (Margetts & Nelson, 2000:427), The half-life of fibrinogen is 4 days; the trial 
. could thus have been conducted over a short period of time, Due to the diversity of 
plasma fibrinogen and possible interactions of factors influencing the concentration, more 
useful data could be collected over a longer period of time and may thus increase the 
statistical power (Margetts & Nelson, 2000: 427). The time frame for this study was thus 
extended to a period of 12 weeks to compensate for the lower number of subjects, 
3.6.2 Sampling procedure 
The Vaal Triangle population was divided into groups, consisting of the different towns 
in the Vaal Triangle. The names of the suburbs per town were thrown in a hat and drawn, 
Thereafter the names of all the schools, tertiary institutions and clinics in the selected 
suburbs were thrown into a hat. One school or tertiary institution and one clinic per 
suburb were drawn from the hat to form part of the sample population, 
The sample population of 100 was randomly divided into two groups of equal size, The 
one group consisted of 50 subjects forming the experimental group, The experimental 
group consumed vitamin A fortified sugar for a period of 12 weeks. The second group 
consisted of 50 subjects forming the control group who consumed non-fortified sugar for 
a period of 12 weeks. 
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3.7 Questionnaires 
The verification, completion and interpretation of the questionnaires formed part of Dr. 
Wilna Oldewage-Theron Ph.D study (Oldewage-Theron, 2001). The questionnaires 
included: 
• Demographic questionnaire: Included questions on age, home language, and the 
number of residents and rooms in the household. The residence setting and the 
responsible person for preparing meals in the household were also noted. Alcohol 
consumption and smoking habits were also questioned. The questionnaire also 
determined the prevalence of high blood pressure, diabetes mellitus, stroke and 
obesity in the family. Habitual sugar consumption patterns were also assessed using 
this questionnaire (Annexure 7). 
• Health and medication questionnaire: The validated health questionnaire of the 
Gauteng Provincial Administration (GPA) was used to assess the general health of 
participating subjects (Annexure 8). A complementary medication questionnaire was 
drawn up and included questions on types brand names and dosages of medication 
taken regularly (Annexure 9). 
• Quantified food frequency questionnaire (QFFQ): The validated QFFQ that was 
used in the THUSA study (MacIntyre, 1998:200) was used in this study to obtain 
qualitative, descriptive information about usual food consumption patterns, 
specifically those containing vitamin A and iron (Annexure 10). 
• Food diary: The food diary served as reference measure for the QFFQ. The main aim 
was to determine whether the subjects consumed vitamin A-rich foods and also to 
determine sugar consumption patterns during the trial (Annexure 11). 
• Reproducibility: Ten Vaal Triangle Technikon student volunteers were used in the 
reproducibility testing of all the questionnaires, except the QFFQ. Subjects completed 
the questionnaires after fieldworkers explained the purpose and content of each of the 
questionnaires. Repeated interviews took place for four consecutive weeks after the 
first interview. The subjects were randomly assigned to the fieldworkers and were 
not necessarily interviewed by the same fieldworkers. This was done to eliminate 
observer bias. All the completed questionnaires were statistically analysed to detect 
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variances for individual subjects. No consistent pattern of variances was reported. 
MacIntyre (1998:221) using 74 volunteers tested the relative validity of the QFFQ in 
the THUSA study. The reference measurements were a seven-day weighed records 
and an attempt was made to validate nitrogen intakes against nitrogen excretion in 24-
hour urine collections. The reproducibility of the QFFQ was tested on a sub-sample 
of 125 volunteers from the THUSA study. The purpose was to obtain the same results 
when administered to the same subjects at different times. The QFFQ was completed 
by means of an interview at an interval of six to 12 weeks between repeat 
administrations. Reproducibility was tested for energy, macronutrients, cholesterol , 
calcium, iron, vitamin A and vitamin C (MacIntyre, 1998 :221). 
3.8 Anthropometry 
Anthropometry is the measurement of body size, weight and proportions and is valuable 
in monitoring the effects of nutritional interventions for disease or malnutrition. 
The WHO recommended height-for-age and BMT-for-age as anthropometric indicators 
for adolescents (WHO, 1995:27 1). For this reason weight, height, and weight-for- height, 
hip- and waist circumference were recorded during weeks I, 4, 8 and 12 of the trial. 
These measurements are among the most fundamental and easily obtained 
anthropometric measurements. A graphical record was kept for each subject, and it 
allowed for the repeated measurements to be plotted on the reference percentiles. 
All the subjects were weighed in light clothes without shoes on a portable electronic 
bathroom scale. Two measurements were made and were not to vary by more than 0,5 
kg. Two measurements for height were made with no more than 0,5-cm variance. Height 
was measured with an upright stadiometer placed against a perpendicular wall at the 
clinics and tertiary institutions. Body mass index (BM!) was calculated using the formula 
weight (kg)/height (m'). 
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3.9 Blood sample collection 
Blood was drawn from the vena cephalica of seated subject after an 8-12 h fast using a 
21-gauge butterfly needle with minimal use of tourniquets. A qualified nursing sister 
collected the blood samples from the subjects. Vacutainer blood collecting tubes were 
labeled in advance with the subject' s trial number as well as the week number. 
Blood was collected as follows: 
• Sml Blood in an EDTA tube (purple lid) (Vacutainer TM_ lot no 9S001) for full blood 
counts (Hb, Hct, RBC, MCV, Pit and WBC). 
• 10 ml Blood in a silicone-coated tube (Vacutainer ®-Iot no 9Y122) for preparation of 
serum for the analysis of iron, ferritin, transferrin, sTrF. 
• JO ml Blood in a silicone-coated tube (Vacutainer ®-Iot no 9Y122) for preparation of 
serum for the analysis of serum retinol. This tube was immediately (after collection) 
protected against UV light, by covering the tube with aluminum foil. 
• 4.5 ml Blood in a tube containing 0.5 ml sodium citrate (0 , II mollL) (Vacutainer TM_ 
lot no 9W139) for the preparation of plasma to measure fibrinogen levels. 
3.10 Sample handlin2 
Blood was separated (centrifuged at l.SOOXg for 20m in .) within 2 hours of blood 
collection. Separated plasma and serum was eliquoted in marked Eppendorf test tubes. 
Two qualified medical technologists continuously audited the separating procedure. 
Citrated plasma was stored at 15°C until assayed. Once plasma has been separated, 
fibrinogen concentration remains fairly stable for up to about 24 hours but may 
deteriorate unpredictably. Plasma can, however, be stored at low temperature for analysis 
(Meade, 1997: 14). Serum for the analyses of iron, ferritin , tranferrin and soluble 
transferrin receptors were stored at -JO·C. Serum for serum retinol was covered by 
aluminum foil and stored at -I O·C until it was couriered to the SAIMR central laboratory 
in Johannesburg. The EDTA tubes were directly placed on a sample tube mixer for 
immediate analyses. 
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3.11 Laboratory test procedure 
A double baseline measurement was done one week apart before commencing with the 
trial. The same biochemical measurements were repeated during the baseline 
measurements, 4th, 8t\ and 12th week of the trial. A total of 500 blood samples were 
collected for the determination of serum retinol, full blood count, iron, ferritin , 
transferrin, sTrF, and plasma fibrinogen. 
Table 13 A summary of methods used to determine serum variables 
Variable Method 
Haematocrit (Het) Numeric integration 
Haemoglobin (Hb) Cyanmethaemoglobin-colorimetric 
method 
Mean cell volume (MCV) Impulse generating 
Red blood cell count (RBC) Coulter counter; ABX MICROSCT 
White blood cell count Coulter counter; ABX MICROSCT 
(WBC) 
Serum iron Coiorametric; Roche Unimate 5 Iron 
Serum ferritin Immunoturbidity~ Roche Unimate 3 
FERR 
Transferrin Irnmunoturbidity; Roche Unimate 3 
TRSF 
s· Transferrin receptor Orion Diagnostica lmmunoturbidity 
assay at 600 nm 
Plasma Fibrinogen Modified Clauss Method 
• Coefficient a/variation: standarddeyiqtion X 100 % 
mean 
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Vaal Triangle Technikon 
Vaal Triangle Technikon 
Vaal Triangle Technikon 
Vaal Triangle Technikon 
Vaal Triangle Technikon 
Vaal Triangle Technikon 
Vaal Triangle Technikon 
Vaal Triangle Technikon 
Vaal Triangle Technikon 
Vaal Triangle Technikon 
Coefficient 
variation* 
1.97 
1.52 
1.16 
0.36 
1.66 
.024 
0.02 
0.09 
1.79 
0.56 
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a) Full blood count 
Full blood count (RBC, WBC, Hb, Hct, MCV) was done on a haematology auto-analyser, 
the ABX MICROSCT within 6 hours of blood collection on a well mixed EDT A sample: 
• The cell counting (RBC, WBC) principle is based on an impedance variation 
generated by the passage of cells through the calibrated micro-aperture. The sample 
is diluted in an electric diluent (current conductor). The dilution is pulled through the 
calibrated micro-aperture. Two electrodes are placed on each side ofthe aperture. An 
electric current passes through the electrodes continuously. When the cell passes 
through the aperture, electric resistance between the two electrodes increases 
proportionately with the cell volume. Two measuring chambers and detection circuits 
separately carry out the analysis of white blood cells and red blood cells. Each type 
of cell is analysed by the microprocessor. 
• To determine the Hb, venous EDT A blood is mixed with a reagent that contains 
potassium ferricyanide (K [Fe (Cn)]) and potassium cyanide [KCN]. The 
ferricyanide oxidises the iron in the haemoglobin, thereby changing haemoglobin to 
methaemoglobin. The methaemoglobin binds with the cyanide to form 
cyanmethaemoglobin. The cyanmethaemoglobin produces a colour measured by 
spectrophotometry, at a wavelength of 550 nm. 
• MeV: The height of the impulse generated by the passage of a red cell through the 
micro-aperture is directly proportional to the volume ofthe analysed cell. 
• The Hct is measured as a function of the numeric integration of the MCV. 
Hct = MCV x RCC 
10 
b) Serum iron 
Serum iron was measured using the Roche Unimate 5 Iron (8X30 ml) (Cat. no. 07 5181 
2). Colorimetric test with Ferrozine ® or ascorbic acid on a COBAZ MIRA autoanalyser 
(The Sceintific Group South Africa). Iron is released from transferrin by guanidine 
hydrochloride and reduced to Fe2+ by ascorbic acid. Bivalent iron forms a red coloured 
complex with Ferrozine. The colour intensity is directly related to the iron concentration 
and is measured photometrically at 560 nm. 
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c) Serum transferrin 
The Roche unimate 3 TRSF (4XIX5 mL) (cat. No.07 3708 8) an immunoturbidimetric 
assay® was used to measure serum transferrin. The procedure was done on the COBAZ 
MIRA autoanalyser. Human transferrin forms a precipitate with a specific antiserum, which 
is determined turbidimetrically (measurement of cloudiness) at 340 nm (fixed time 
method) . 
d) Serum ferritin 
The Roche Unimate 3 FERR (IX20 ml) (cat. no. 07 51820) a latex immunoturbidimetry 
was used to measure the serum ferritin levels. Human serum ferritin forms a precipitate 
with the suspended anti-ferritin coated latex particles. These results in an increase in 
turbidity that is determined turbidimetrically (measurement of cloudiness) at 600 nm 
(fixed time method). 
e) Soluble tranferrin receptor (sTiR) 
The IDeA® sTfR-IT (The Scientific Group cat no. 67968) assay is based on the detection 
of an immunoprecipitation between sTfR in the sample and sTfR-specific antibodies on 
latex particles. The assay is standardised against human serum sTfR. Measurements were 
performed on the COBAZ MIRA autoanalyser. 
f) Serum retinol 
The first valid method available for the determination of serum vitamin A levels was a 
bioassay. A spectrophotometric method and a photometric method were established later. 
Both the spectrophotometric and the photometric method are liable to interference, since 
some substances (mainly caratonoids, derivatives and decomposition products of vitamin 
A) may absorb light in the same ultraviolet region or give similar colors with the reagents 
used. Above mentioned methods are not specific for vitamin A and the reliability depends 
on the purification methods. High Performance Liquid Chromatography (HPLC) is a 
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more precise, accurate and faster procedure and currently the widest used method 
(Bohman et al., 1982:251 ). 
A chromsystem high performance liquid chromatography (HPLC) column (CS34100, 
Separations) for analysis of vitamin A in serumlplasma was used to determine of serum 
retinol levels. An internal standard is added to a serum sample. Proteins are precipitated 
and the retinol extracted into isopropanol. After centrifuging the sample, the organic layer 
is pipetted off and injected onto the column. 
g) Plasma fibrinogen 
Plasma fibrinogen levels were determined within 8 hours after collection of the sample 
by means of the Dade Behring - Multifibren® U method (a modification of the Clauss 
method). Citrated plasma is coagulated by adding a large excess of thrombin. The 
coagulation time depends on the fibrinogen content of the specimen: substances that 
inhibit thrombin do not affect this test. Plasma (100 ilL) is added to a 37°C pre-warmed 
test tube, incubated for 60 seconds, whereafter 200 ilL Multifibren U reagent, pre-
warmed to 37°C, is added and the clotting time determined. Fibrinogen concentration 
(gIL) is obtained by using a reference curve prepared in the laboratory, using standard 
plasma (lot. no 519857) 
The Multifibrin U composition consists of bovine thrombin (50 IU/ml), fibrin-
aggregation retarding peptide (gly-pro-arg-pro-ala-amide, 0, IS giL), calcium chloride 
(I,5g/L), hexadimethrine bromide (IS mg/L), polyethylene glycol 600 (0,8 gIL), sodium 
chloride (6,4 gIL), Tris (50 mmollL), and bovine albumin (10 giL) . 
h) Quality control 
Proper quality control is an important aspect of any laboratory test procedure. The 
following quality control procedures were followed for each test: 
• Fibrinogen: A reference curve was establ ished using fibrinogen 
standards (Dade Behring fibrinogen standard, lot no. 519855). These 
standards were tested as samples. Values obtained were plotted on a 
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log-log format. Checking the values of control plasma (Dade Behring 
control plasma N (lot no. 502711) and P (lot no.512651)) after every 
15 tests monitored accuracy of the procedure. Control values did not 
vary more than 2SD from the prescribed mean. 
• Full blood count: EIGHTCHECK-3WP-N (lot no. SFN-IOOB), 
EIGHTCHECK-3WP-L (lot no. SFN-IOOB) and EIGHTCHECK-
3WP-H (lot no. SFN-IOOB) were used as haematology control blood. 
EIGHTCHECK-3WP-N is for normal values, EIGHTCHECK-3WP-L 
is for low abnormal values and EIGHTCHECK-3WP-H is for the high 
abnormal values. Control blood contains stab ili sed human red blood 
cells, fixed mammalian white blood cells and platelet components in a 
medium containing preservatives. 
• Iron, Transferrin: OLYMPUS control serum level 1 (ODC0003 lot 
no. 014) and level 2(ODC0004 lot. no. 014) were used to monitor the 
accuracy and precision of automated analytical assays of ferritin and 
transferrin. It is a Iyophilised serum of human origin. The 
concentration and activities of level ] are in the norma] range, and 
level 2 in the pathological range. Control serums were repeated after 
every 15 samples. Control values did not vary more than 2SD from the 
prescribed mean. 
• Ferritin: A FERRfMYO T Control (Roche lot no. 0751863) is a 
Iyophilised preparation of human ferritin and myoglobin used to 
monitor the accuracy and precision of assays of ferritin and 
myoglobulin. Assigned values were printed on each vial label. Control 
serum was repeated after every IS samples. Control values did not 
vary more than 2SD from the prescribed mean. 
• sTrF: IdeA sTfR control serum (The Scientific Group cat no. 67968) 
high and low were used and treated as a sample. Control values did not 
differ more than 2SD from the mean. 
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• Serum retinol: Vitamin A control serum, level I (normal) and level 2 
(abnormal) (Separations cat no. CS0032) were used and treated as a 
sample. Control values did not differ more than 2SD from the mean. 
3.12 Statistical analysis 
The results of the blood analyses were computerised and stati stically analysed by a 
qualified statistician using the SPSS for windows ® programme version 6.0. Changes 
from baseline to the end of the 12-week study in the experimental group for all variables 
were compared with those in the control group by using the Levene's two-tailed test for 
equality of variances. Paired tests were done to compare for significant differences within 
groups. Differences were considered to be statistically significant if p< = 0,05. Pearson 
correlation coefficients were used to test for associations between biochemical- and 
haematological variables, as well as between dietary and biochemical- and 
haematological variables. A correlation was considered to be present if r => 0 with 
significance level P = 0,001 , 0,05 or O,\. 
The data entry programmes had a number of quality control mechanisms, including 
validity checks, duplicate detection and verification procedures, written in SPSS. All 
programmes were introduced and standard isation exercises performed at the time of 
training the research assistant. 
3.13 Researcher's contribution 
Contributions made by the researcher were: 
• Standardising laboratory infrastructure (Apparatus placements, reagent purchasing, 
and apparatus calibration). 
• Training of the nursing sister for fieldwork. 
• Manage the laboratory test procedures and quality control programme. 
• Co-ordinate consigns ofthe vitamin A samples. 
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All the blood samples were prepared and handled by a registered medical technologist 
under controlled and standardised conditions. One of the most important attributes of the 
project was the importance placed on the quality of the data. The registered medical 
technologist monitored each round of data collection; the blood collection points were 
checked and laboratory quality control managed, as well as supervising the data 
collection. Detailed monitoring checklists were maintained to verify whether appropriate 
techniques were being employed for each point of the data collection. The laboratories 
involved in the analysis used standard techniques according to accreditation procedures. 
3.14 Research team contribution 
Contributions made by other research team members were: 
• Dr. Wilna Oldewage-Theron co-ordinated and administrated the project as project 
leader. This study was also a under-study of Dr. Wilna Oldewage-Theron's PhD 
study 
• Emsie Dicks studied the compliance and consumer acceptability of the fortified sugar. 
• Mosa Selepe did the nutritional data gathering and analyses. 
• Jose van Rensburg assisted in blood analysis. 
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CHAPTER 4 
RESULTS 
4.1 Introduction 
The focus of this dissertation is on the effects of the intake of a vitamin A fortified 
product on plasma fibrinogen levels. However, to interpret the changes in plasma 
fibrinogen, changes in other measured variables as reported by Oldewage-Theron (2001) 
are also given. 
Results reported in this chapter are: dietary patterns, food diary, changes in the vitamin A 
and plasma fibrinogen status. The correlation between vitamin A and other variables and 
the correlation of plasma fibrinogen level with relevant variables will also be indicated. 
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4.2 Dietary patterns of the sample population 
4.2.1 OFFO results 
The QFFQ's were analysed to determine the food items most often consumed by the 
sample population, and are summarised in Table 14. 
Table 14 Top 22 items consumed by the sample population (P = 0,05) 
Food hem Mean daily intake Number of subjects with daily 
(gram per person) consumption 
Tea, brewed 267,3 74 
Coffee, brewed 177,9 60 
Cold drink 160,1 75 
Milk, whole, fresh 101 ,8 90 
Fruit juice 93,95 40 
Yoghurt, low fat, flavoured 81,85 59 
BreadlRolls 77,1 90 
Maize porridge, cooked 63,6 90 
Oats porridge, cooked 52,3 55 
Malt beverages 50,1 32 
Rice, white, cooked 45,7 88 
Apple, raw 43,S 83 
Potato chips (French fries) 42,8 58 
Maltabella, uncooked 39,4 52 
Breakfast cereals 34,6 50 
Banana, raw 34,2 80 
Macaroni/spaghetti, cooked 32,4 67 
Sugar, white 31 90 
Polony 30,1 80 
Cabbage, cooked 28,1 10 
Mageu 27,1 19 
Mango, raw 26,7 71 
Table 14 shows that the six top items by weight consumed by these subjects, were tea, 
coffee, cold drinks, milk, fruit juice and yoghurt, indicating a westemised-type diet. Maize, 
the staple food of Africans in SA, was 8th on the list, and mean daily intake of maize 
porridge was only 63,6 g, The daily mean consumption of sugar was 31 g. The mean sugar 
consumption over the 12 weeks increased, varying from 98,67 g per day in week 1 to 
63,66 g per day during week 12, The QFFQ mean sugar intake, measured at baseline, 
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was reported to be 31 g per day. The subjects thus reported much higher intakes when 
completing the food diaries. A possible reason for the higher consumption could be that 
the sugar was given to the subjects for free and that this encouraged them to consume 
more sugar than usual. This was particularly true for the first month after they had 
received the sugar (mean daily intake of 98,67 g). This reported high intake decreased 
gradually until the end of the study. 
In addition to fruit juice, three other fruits namely apple, banana and mango were under the 
top 22 foods consumed. Of these foods , mango would contribute substantially to vitamin A 
intake, containing 66 ~g RE vitamin A and 395 l3-carotene equivalents in total carotenoids 
per 100 g (Kruger, et 01., 1998:52). It is noteworthy that unless fortified (malt beverages 
and breakfast cereals) no special rich source of iron (red meat, spinach) appeared in this list. 
4.2.2 Food diary results 
The nutrient analysis of the food diaries that the subjects kept to monitor intake of a 
selected group of foods rich in vitamin A and iron (see Annexure II) is given in table 15. 
The vitamin A added to the sugar, which the experimental subjects consumed, is not 
included in the analysis. (See table 15) 
Table 15 Analysis offood diaries: daily mean intakes from selected items 
Nutrient and Week 1 Weak 4 Week 8 Week 12 
unit measurement measurement measurement measurement RDA<ltIRNI-
Energy (kJ) 4785±2632 4296±2234 3922±1657 4227±1307 
Protein (g) 28.1 ± 21 .1 29,92±18,4 30,18±17,7 32,11±18,6 56' 
Fat (g) 58,01 ± 51,2 54,12±46,4 49,5±30,4 52,25±21,6 
Cholesterol (g) 498,9 ± 451 ,6 561 ,51±395,7 551 ,23±349,6 505,15±350,3 
Carbohydrates(g) 129,12 ± 55,4 105,54±45,5 93,41±33,6 102,07±34,7 
Sugar (g) 98,67±50,25 76,25±40,0 64,5±26,55 63,66±25,9 
Dietary fibre (g) 5,06 ± 3,8 5,60±4,7 5,42±3,7 7,61±3,7 
Calcium (mg) 536,89 ± 459,9 484,46±361,7 478,21±356,1 583,08±386,7 700** 
Iron (mg) 4,83 ± 4,4 5,56±4,6 5,80±4,1 6,00±4,8 14,8-
Sodium (mg) 652,54 ± 498,0 647,66±395,1 631 ,83±354 ,3 767 ,46±349,0 1,6-
Vitamin A (~g 1068±560 1201±959 1220±843 1349±954 1000*/600** 
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Nutrient and Week 1 Week 4 Week 8 Week 12 
unit measurement measurement measurement measurement RDA'/RNI-
RE) 
Thiamin (mg) 0,33 ± 0,2 0,35±0,2 0,35±0,2 0,40±O,2 0,4 mg/4200 kJ 
-j 
Riboflavin (mg) 1,28 ± 1,1 1,35±1,O 1,41±O,9 1,46±1,0 1,4*/1,1-
Niacin (mg) 2,88 ± 2,5 3,13±2,7 3,34±2,4 3,96±2,7 6,6 mg/4200 kJ " 
Vitamin 86 ("g) 0,54 ± 0,4 0,59±.0,4 0,60±0,4 O,68±0,4 15 ~g/g protein .* 
Folic acid ("g) 268,99 ± 321 ,2 315,95±315,4 353,78±338,4 333,21±375,5 100'/200-
Vitamin 812 ("g) 6,94 ± 8,2 7,93±8,6 8,87±8,5 8,09±9,2 1,6*/1 ,5·· 
Vitamin C (mg) 28,41 ± 26,2 31,45±29, 1 34,19±27,2 41,37±32,5 45'/10-40-
Wamin 0 ("g) 4,35 ± 3,7 5,35±3,5 4,77±2,9 4,56±3,O 
Wamin E(mg) 6,92 ±4,2 7,81±4,4 7,46±3,8 8,62±3,7 3-
* The Recommended Daily Allowances (RDA'S) for South African women, The 
RDA is the daily dietary intake level that is sufficient to meet the nutrient 
requirements of nearly all (97-98 %) individuals in a given life-stage and gender 
group. 
** Reference Nutrient Intake (RNI) for the women in the United Kingdom. These 
intake levels should satisfy 97 % of the daily nutrient requirements . 
The iron provided by these specifically selected foods rich in iron was between 50 % and 
65 % of daily requirements, Mean vitamin A intakes (without the fraction provided by 
the fortified sugar) was also relatively constant varying from 1068 to 1349 ~g RE, This 
was substantially higher than the 600 - 1000 ~g RE recommended. However, the 
standard deviations were large, illustrating the large variability in intakes between 
subjects, The mean sugar consumption over the 12 weeks increased, varying from 98,67g 
per day in week 1 to 63,66 g per day during week 12. The QFFQ mean sugar intake, 
measured at baseline, was reported to be 31 g per day. 
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4.3 Vitamin A status 
4.3.1 Baseline Vitamin A results 
>50ug/dl 
15.7% 
40-50ug/dl 
38.6% 
Figure 9 Baseline Vitamin A status 
<30 ug/dl 
12.0% 
30-40ug/dl 
33.7% 
Baseline measurements of serum vitamin A indicated: 12% of respondents had a serum 
retinol of < 30 J.lgldl, 33.7% a level of 30J.lg/dl -40J.lgldl, 38.6% had a level of 40J.lgldl -
50J.lgldl and 15.7% of respondents had a serum retinol level of > 50J.lgldl. 
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4.3.2 Changes in VA status during VA fortification period 
Table 16 
No 
4 
5 
7 
10 
16 
18 
22 
23 
25 
27 
28 
30 
31 
41 
44 
50 
52 
53 
54 
56 
58 
60 
62 
63 
64 
65 
66 
67 
68 
70 
71 
72 
73 
76 
Comparison of individual serum retinol levels (llgldL) at baseline and 
after 12 weeks (t increase, .,l. decrease, ~ no change) 
Experimental group Change No Placebo group Change 
Baseliof' Week 12 ( > 5 g/dLJ Ranline Week 12 ( > 5 g/dLJ 
(pg/dL) (l'&/dL) (pg/dL) (pg/dLJ 
4 1,7 47,8 t 1 36,8 36,7 ... 
57,2 57,0 .... 2 55, 1 55,0 ... 
45,S 59,0 t 3 36,8 47,S t 
49,9 72,0 t 6 42,2 65,0 t 
37,6 37,4 ... 11 21,2 35,0 t 
4 1,3 66,8 t 13 44,2 45,0 ... 
40,8 69,7 t 15 34,0 73,7 t 
40,2 64,3 t 17 43,1 55,3 t 
56,S 64,2 t 20 24,3 24,1 ... 
49,8 67,0 t 21 38,0 45,3 t 
45,2 48,0 <-> 26 59,0 36,6 .j, 
lOS,S lOS,S ... 32 2 1,S 36,4 t 
25 ,S 26,1 <-> 34 78,2 52,8 .j, 
107,1 71 ,0 .j, 35 36,3 35,0 .... 
29,4 34,7 t 37 39,8 39,9 .... 
47,2 48,1 ... 42 32,4 39,0 t 
59,9 61,3 <-> 46 33,0 47,9 t 
57,3 61,4 ... 47 64,S 25,7 .j, 
44,1 50,3 t 48 34,2 36,8 ... 
63,3 69,3 t 49 77,0 64,6 .j, 
31,3 31,4 .... 55 48,8 66,0 t 
24,8 30,3 t 57 31 ,2 26,0 .j, 
60,8 47,1 .j, 61 40,2 25 ,2 .j, 
45,1 26,8 .j, 69 43 ,9 44,6 ... 
45,0 36,9 .j, 74 41 ,0 42,8 .... 
35,0 43 ,4 t 75 42,6 44,0 ... 
65,0 71 ,0 t 80 53,0 48,0 <-> 
29,0 30,2 .... 83 41 ,0 41,4 <-> 
33,7 41,2 t 85 31 ,0 25,6 .j, 
37,2 17,9 .j, 86 40,0 40,8 .... 
43 ,8 38,3 .j, 90 29,6 29,6 <-> 
43 ,6 55 ,0 t 91 23 ,1 33,0 t 
43 ,3 36,0 .j, 93 44,0 34,6 .j, 
24,9 43,7 t 94 51,S 29,7 .j, 
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Experiments Change No Placebo group Change 68,9 t 
No I group 
Baseline Wee" 12 ( > 5 g/dl) Bastlioe Week 12 ( > 5 g/dl) 
(\1g/dl) (\1g/dl) (\1g/dl) (\1g/dl) 
79 66,0 74,7 t 97 38,8 52,6 t 
81 51 ,0 43,4 • 98 34,3 34,3 .. 
82 44,0 53,3 t 99 59,6 56,2 .. 
84 47,0 54,0 t 100 32, 1 38,4 t 
87 38,5 52,1 t 
89 35,6 47,7 t 
92 35,5 52,8 t 
t 23 53,5% t 15 37,5 % 
• \I 25,6% • 9 22,5 % 
... 9 20,9% .. 16 40, 0% 
4.4 Fibrinogen status 
4.4.1 Baseline fibrinogen results 
>3.39/1 
11.1% <2.1 911 
5.1% 
2.12-3.3 
83.8% 
Figure 10 Baseline plasmafibrinogen status 
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There is some controversy in the literature about a "normal" plasma fibrinogen level 
(Vorster, 2000) and the level at which it statts to operate as a CHD risk factor. The 
Northwick Park Heart Study (Meade fLIll ., 1986) showed that one standard deviation 
increase (0,60 giL) in fibrinogen was associated with an 84 % increase in CHD risk. The 
mean levels of fibrinogen (2,81 giL) found in these women were similar to levels found by 
Venter ~. (1992) in Tswana-speaking black men and women of approximately 2,8 giL. 
These were significantly higher than levels in white control subjects. It seems therefore that 
the subjects in this study had relatively high levels of plasma fibrinogen 
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4.4.2 Changes in fibrinogen status during VA fortification period 
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Table 17 Changes in plasma fibrinogen and related variables during VA 
fortification 
l!ixperlmenlal group (n - 44) Placebo group (0 = 40) 
Variable Normal range Week 011 Week4 WeekS Week 12 Week 0/1 Week 4 WeekS Week 12 
aDd unit 
Fibrinogen 2,72 - 3,30 giL 2,82 o.b 2,65· 2,67 b 2,84 2,68 2,76 2,75 2,86 
(mean) .0,47 ±0,52 .0,68 ±0,49 .0,37 .0,85 .0,54 .0,58 
±SD 
wee (mean) 3,5-10,0 X 4,96",b 4,52 5,08 • 4,98 b 5,27 5,04 5,52 5,1 1 
±SD IOl/mm1OR ±1,23 ±1,37 ± 1,35 ± 1,47 ±I ,6 ± 1,61 ± 1,58 * 1,61 
3500-10000 
BMI (mean) 20 - 25 kglm2 22,0· 22,0 22,0 22,4· 22, 1 22, 1 22,2 22,4 
±SD ±4,0 1 ±4,11 ±4,07 ±3,83 ±3, 13 ±3,06 ±3,16 ±3,03 
WaistHip ratio 0,75 0,74 · 0,74 0,73 • 0,73 0,73 0,73 0,73 
(mean) ±O,05 .0,05 ±0,05 ±0,05 .0,05 .0,05 .0,05 
±SD 
Serum retinol ~ 30 ~gidL 47,0 a,b 43,90 51,90' 49,20 b 43 ,30 43 ,30 49,50 
(mean) ± 17,20 ± 14,40 ± 14,40 ± 14,80 ± 14,70 ± 12,00 ± 14,00 
±SD 
Means with the same symbol differs significantly within groups. The same subjects have 
been used throughout the trial. 
Table 17 gives the changes in plasma fibrinogen observed during the 12-week intervention 
period, as well as changes in serum retinol, WBC and BMl. It is clear that no significant 
changes for any of these variables occurred in the placebo group. Despite only small, but 
statistically significant changes in serum retinol at 8 and 12 weeks, plasma fibrinogen 
decreased significantly after four and eight weeks in the experimental group, but returned to 
baseline values after 12 weeks. White blood cell counts were significantly higher in the 
experimental group after eight weeks while BMI was significantly higher in this group after 
12 weeks compared to baseline. 
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Figure 15 Summary of changes in plasma fibrinogen levels observed. 
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Figure 16 gives the changes in BMI observed during the 12 weeks in the experimental and 
control group in the placebo group. A statistically significant (a=O.OI) increase in BMI 
occurred during the 12 week intervention in both placebo and control groups. 
Table 18 Summary of tlte BMI classification during tlte intervention period 
Summary table of cut-off pOints for the variable : 8MI 
Percentage of 
respondents <= 18.5 (UnderweiQht) 
Percentage of respondents 
> 18.5 and <= 25 (Normal weicht) 
Percentage of respondents 
> 25 and <=30 (Overweicht) 
Percentage of 
resDondents> 30 (Obese) 
F = Fortified group (experimental group) 
N = Non-fortified (control group) 
F 
N 
F 
N 
F 
N 
F 
N 
F: n ;: 
N: n -
Baseline 
15 .22 
13 .95 
71.74 
74.42 
8 .7 
9 .3 
4.35 
2.33 
46 
43 
Week 4 Week 8 
15.22 13.04 
13 .95 13.95 
71.74 76.09 
74.42 72 .09 
8 .7 6.52 
9.3 11 .63 
4.35 4.35 
2.33 2 .33 
46 46 
43 43 
4.6 Correlation between serum retinol and other variables 
Week 12 
11 .11 
9.3 
68.89 
74.42 
15.56 
13.95 
4.44 
2.33 
45 
43 
Table 19 Correlations between serum retinol and otlter serum, blood and plasma 
variables and BMI as per Pearson correlation (two-tailed) 
Variable Baseline (o=lOO) At eDd of study (week 12) (n - 83) 
Serum retinol with: 
r p r p 
Red blood cell count 0,052 0,642 0,237' 0,031 
Hb 0,295 0,007 0,322' 0,003 
Bet 0,296 0,007 0,303' 0,005 
Mean cell volume 0,288' 0,008 0,183 0,098 
White blood count 0,201 0,068 0,009 0,933 
Serum iron 0,413' 0,000 0,407' 0,000 
Ferritin 0,316' 0,004 0,270' 0,014 
Transferrin -0,164 0,140 -0,116 0,014 
S-transferrin receptor -0,312' 0,004 0,205 0,063 
Fibrinogen 0,092 0,408 0,067 0,547 
Body mass index 0,195 0,079 0,402' 0,000 
. 
t ,', B' C. !J 
II r.t_ rrit.)P:EJlrY * Correlation is significant at the 0,05 level (two-tailed) 
OF TriE j z / , .. . ,. 
• 
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Table 19 gives the correlations between serum retinol and some of the other biochemical 
variables. At baseline serum retinol showed significant positive correlations with Hb, 
Hct, mean cell volume, serum iron and ferritin. No significant relationships with BMI, 
fibrinogen and transferrin were observed. However, a highly significant negative 
relationship with the serum transferrin receptor (r = -0,312; P = 0,004) was found at 
baseline. 
At the end of the study of 12 weeks, during which half of the subjects consumed vitamin 
A fortified sugar, a significant relationship between serum retinol and red blood cell 
count emerged, as well as a significant negative correlation between transferrin and 
serum retinol. The other correlations observed at baseline were also apparent at 12 
weeks, except that the correlation of serum retinol with the serum transferrin receptor was 
no longer significant (r = -0,025; P = 0,063). 
4.7 Correlation between fibrinogen status and other variables 
Table 20 Correlations between fibrinogen and all the other variables as per Pearson 
correlation (two-tailed) 
Variable Baseline (n-IOO) At end ofstudy (Week 12) 
(n~ 83) 
r p r P 
Serum retinol 0,092 0,408 0,067 0,547 
Red blood cell count 0,075 0,499 ·0,090 0,421 
Hb -0,021 0,853 0,124 0,263 
Het 0,008 0,946 0,119 0,285 
Mean cell volume ·0,072 0,5 16 0,229' 0,037 
White blood count 0,243' 0,022 0,113 0,293 
Serum iron ·0,001 0,994 0,019 0,864 
Ferritin 0,262' 0,017 0,053 0,633 
Transferrin ·0,107 0,336 ·0,217' 0,048 
S-transferrin receptor 0,206 0,062 ·0,086 0,442 
Body mass index 0,232' 0,033 0,257' 0,018 
* Correlation is significant at the 0,05 level (two-tailed) 
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Table 20 shows that in these subjects serum retinol were not related to plasma fibrinogen. 
Plasma fibrinogen showed significant positive correlations with the white blood cell count, 
ferritin and BMI. The relationship between plasma fibrinogen and the serum transferrin 
receptor was significant on a 6 % level (r = 0,206; P = 0,062) at baseline, but was not 
observed after 12 weeks, and was probably not reflecting a real association. 
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4.8 Drop outs 
At the end of the 12-week experimental period, 83 subjects completed the study protocol 
successfully and 17 % were lost to the study. A total of 40 subjects remained in the 
experimental group compared to 43 in the placebo group. The details of subjects who were 
lost to follow-up are compared to those of the subjects who completed the study in Table 21. 
Table 21 Baseline characteristics of participants witll those lost to follow-up and 
thus excluded* 
Baseline measurement l'articipants (n - 83) Drop·outs (n s 17) 
Mean± SD Mean ± SD 
Body weight (kg) 56,20 ± 12,32 • 65,11 ± 8,21 • 
Body mass index (kglm') 21,86 ± 3,53 b 24,06 ± 2,46 b 
Fibrinogen (gIL) 2,99 ± 0,51 2,70 ± 0,95 
White blood cells (10' Imm' ) 5,25 ± 1,56 4,74 ± 1,46 
Temperature ee) 36,80 ± 0,52 38.80 ± 0,35 
Systolic blood pressure (mm Hg) 105,30 ± 11 ,10 103,50 ±\3,20 
Diastolic blood pressure (mm Hg) 69,50 ± 8,70 72,90 ± 8,49 
Serum iron (~mollL) \3,42± 6,50 13,69±6,15 
Transferrin (giL) 3,5H 0,56 3,40 ± 0,55 
Ferritin (ng/mL) 26,07 ± 24,32 24,47 ± 24,37 
Haemoglobin (gldL) 13,33 ± 1,50 \3,45 ± 1,12 
Haematocrit (%) 35,35 ± 3,48 35,60 ± 2,77 
Mean cell volume (fl) 83,24 ± 7,63 85,18±7,51 
Red blood count (1O'/mm') 4,24 ± 0,29 4,13± 0,38 
Serum retinol (IlmollL) 1,93 ± 1,02 1,53 ± 0,75 
a, b: means WIth the same symbol dIffer sign Ificantly (P < 0,05) 
• • Values are means with 95 % confidence interval. Seventeen subjects were lost to 
follow-up (Levene's test for equality of variances, P = 0,05). 
The only statistically significant differences between the participants and the drop-outs 
were body weight and BMI. The drop-outs had a higher mean weight and BMI than the 
participants. 
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CHAPTERS 
COMBINED DISCUSSION, CONCLUSIONS AND 
RECOMMENDATIONS 
5.1 Discussion 
5.1.1 Introduction 
rHl~ BOOK :S 
THE PROPEnn 
Z 4 NOV Z003 
II.:-';n,.,,,UN 
FREE STATE 
The major objectives of this study were to examine the effects of the consumption of 
vitamin A fortified sugar on vitamin A status, and plasma fibrinogen of 13-25 ye\lr 
old black South African girls and women in a double blind placebo-controlled 
parallel designed clinical trial. 
Increased plasma fibrinogen is a major risk factor for eHD (Folsom, 1995:21) and 
stroke (Krobot eLill., 1992:780). Fibrinogen is known to be increased in black 
South Africans (Vorster eLill., 1998:174) and the THUSA study (James .e1...S1J., 
2000:392) suggested that these high levels were associated with undernutrition in 
men and overnutrition and obesity in women. The purpose of this study was to 
assess the relationship between plasma fibrinogen and to test the hypothesis that 
increased intakes of vitamin A will lower plasma fibrinogen. 
Subsidiary objectives were to examine the correlation between plasma fibrinogen and 
wee, red cell parameters, iron status and BMI. 
The high prevalence of both undernutrition (especially of vitamins), and overnutrition 
and high incidence of eVD in SA (especially in black women), motivated this study. 
5.1.2 Limitations of the study 
• The first limitation of this study is probably the choice of subjects. Young 
black women volunteers were chosen, because they were thought to be the 
most vulnerable group regarding vitamin A and iron status, and also a group 
TECHNIKON 
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with the potential of becoming obese and increased risk of CVD in later life. 
For the clinical intervention trial a group of vitamin A deficient subjects could 
have produced more definite results. 
• The second limitation may lie in the exclusion of c-reactive protein (CRP) 
from the test panel. CRP gives a definite correlation between reactive 
condition and the influence on the plasma fibrinogen levels. The collection of 
the blood for the determination of week 12 was done in May. Therefore the 
seasonal change could have an influence on the results of week 12. 
• The third limitation may be the fact that only serum retinol was measured to 
determine vitamin A status. Mahan and Escott-Stump (2000:70) mention that 
the serum retinol levels are maintained between 40 and 50 !!g/dL in healthy 
adults with normal serum retinol levels, and in these subjects 91,7 % had 
normal serum retinol levels (2! 30 !!g/dL). Serum retinol binding protein 
(SRBP) should have been measured to provide additional information. 
• Even though there were no statistical significance between the participants and 
the dropouts it could be considered as a limitation ofthis study. 
5.1.3 Main findings 
The salient findings of this study were: 
• In the 83 subjects who completed the clinical intervention trial, 88 % had 
normal serum retinol levels (2! 30 !!g/dL). Of the experimental group, 23 (53,5 
%) had an increase of more than 5 !!g/dL serum retinol at week 12 compared 
to baseline, while 20,9 % showed no change and 25,6 % had lower levels. 
Comparative figures for the placebo group were 37,5 % that showed an 
increase, 40 % who had no change and 22,5 % that showed a decrease. 
• This intervention study provides some evidence that increased intakes of 
vitamin A by subjects with acceptable vitamin A status resulted in small, but 
statistically significant decreases in plasma fibrinogen. These decreases were, 
however, not sustained, probably because of observed increases in BMI or due 
to seasonal changes. The experimental subjects showed a significantly higher 
BMI at week 12. Meller & Kristensen (1991 :344) found a strong univariate 
association between the waist-to-hip ratio and the fibrinogen levels in a study 
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of 439 51-year-old men. Bao et al (1993:324) demonstrated in the Bogalusa 
Heart Study a consistent increase in fibrinogen levels with ponderal index and 
skinfolds in children. In the THUSA study of Africans in the Northwest 
province of South Africa, BMI showed a significant positive correlation with 
fibrinogen (r=0.25; p=O.OOO) (James et ai, 2000:385). Folsom et al (1991 :200) 
developed two models to predict changes in fibrinogen for a 5_kglm2 increase 
in BM!. The first model showed a 0.85 gIl increase in men and a 1.23g/1 
increase in women, and the second a 0.6 gil increase in men and a 0.98 gIl 
increase in women. It seems reasonable to conclude that this increase in BM! 
has been responsible for the increase in plasma fibrinogen. 
• Higher plasma fibrinogen levels occur in winter compared to levels in the 
summer. Variation in fibrinogen levels can be 5-20% higher in winter than 
in summer. Speculation that higher fibrinogen levels in winter may reflect 
either temperature or acute-phase response to respiratory infections. (Meade, 
1995:33). Week 12 was done in early winter, and can be a possible 
explanation of the dramatic increase in the plasma fibrinogen levels of both 
the experimental and placebo group. Fibrinogen is an acute phase protein. 
The increased white blood cell count of the experimental group at weeks 8 
and 12 could indicate some immune response with concomitant rises in 
plasma fibrinogen. The positive relationships between plasma fibrinogen and 
white blood cell count, as well as ferritin are not unexpected. White blood 
cell count can be expected to increase with infections, and both fibrinogen 
and ferritin are acute phase proteins, known to increase with infection. 
These results suggest that despite the inclusion criterion of "healthy", low-
grade infections were present at baseline in these subjects. 
• The relationship between plasma fibrinogen and serum ferritin (reflecting 
stored iron), and also observed in the BRISK study (Vorster tl.JJl., 1998:174), 
could possibly be because both are acute phase proteins - or there may be 
another mechanism involved. Excess iron is stored in the liver and fibrinogen 
is synthesised and secreted by the liver. However, to claritY these 
mechanisms, much more basic research is needed. 
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• Plasma fibrinogen showed significant positive correlations with white blood 
cell count, ferritin and BMI. The relationship between plasma fibrinogen and 
the serum transferrin receptor was significant on a 6 % level at baseline. 
5.1.4 Possible mechanisms of vitamin A and fibrinogen interaction 
Many demographic and environmental factors are known to affect fibrinogen levels. 
The effect of these environmental factors is largely through an effect on the acute 
phase reaction (Krobot et al., \992:780). It is also known that genetic factors 
determine the fibrinogen levels, and the response of fibrinogen levels to 
environmental factors. Estimates suggested 30-50% of the plasma fibrinogen level is 
genetically determined (Hamstein el aI., 1987:989). 
The effect of dietary components on plasma fibrinogen levels is modest. Several 
components have been identified that have a modest effect on plasma fibrinogen 
levels. Only moderate alcohol consumption was found to have a consistent and clear 
fibrinogen lowering effect (De Maat, 2001 :511). 
These weak associations are surpnsmg, since several dietary components affect 
mechanisms that regulate the fibrinogen synthesis. Dietary antioxidants would be 
expected to protect from processes brought about by oxidative damage, such as an 
upregulation of genes of inflammatory components (De Maat, 2001 :511). 
De Maat (2001 :511) explained the fact that only minimal and often contradicting 
effects of dietary components on fibrinogen levels are observed, may be due to the 
study design. 
The fact that fortified sugar was used in this study, as a supplier of vitamin A may be 
the reason for the unsustainablility of the down regulation of the plasma fibrinogen 
levels in this study. Supplied sugar and the dietary intervention as part of this study 
design, were possibly the reason for the increase in BMI, which also affected the 
plasma fibrinogen level. 
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5.2 Conclusions 
There is some evidence that increased intakes of vitamin A by subjects with 
acceptable vitamin A status resulted in small, but statistically significant decreases in 
plasma fibrinogen. These decreases were, however, not sustained, probably because 
of observed increases in BMI and weight, as well as seasonal changes. 
Although CHD prevalence is still low in black South Africans, it was suggested that 
high fibrinogen levels might be a major risk factor for stroke in this population group 
(Vorster et al., 1998). It seems reasonable to conclude that fibrinogen levels were 
raised in these subjects, that they could therefore be lowered, and that they should be 
lowered to decrease risk for future stroke - even in these young subjects. This 
emphasises the need for lifestyle interventions to lower plasma fibrinogen 
concentrations. 
5.3 Recommendations 
5.3.1 Further research 
The results of this study indicate that further research is needed addressing the 
following issues: 
• The mechanism by which vitamin A and fibrinogen synthesis interact needs 
to be studied and determined in order to plan future intervention 
programmes. 
• Future studies should examine the effect over a longer period of 
consumption. 
• The influence of vitamin A on fibrinogen and its functionality (c1ottable 
protein, changes in turbidity, and immunological method specific for total 
High and low molecular weight fibrinogen (Niewenhuizen, 1995:8), should 
be examined in subjects with raised fibrinogen and low vitamin A status, 
often seen among African adults at risk for cardiovascular disease. 
• Lifestyle intervention studies should be investigated among young South 
African women. The influence of lifestyle practices (like environmental 
pollution, diet and exercise) on plasma fibrinogen levels could be 
investigated. 
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5.4 Practical implications of the results 
This research project provided the opportunity to determine the effect of vitamin A 
fortified sugar consumption on fibrinogen levels in a community and individuals at 
risk of VAD and CVD. It was the first time that an intervention study with vitamin A 
fortified sugar was conducted in South Africa. 
The results of the clinical intervention trial provide information regarding the effect of 
fortified vitamin A on fibrinogen levels of healthy young females. The results could 
therefore have an impact on public health policy regarding the treatment of 
micronutrient, specifically vitamin A deficiencies. Programmes aimed at the 
prevention of micronutrient deficiency, rather than treatment, may help to prevent the 
rising health costs in the country. 
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POTCHEFSTROOMSE UNIVERSITEIT VIR CHRISTELIKE HOeR ONDERWYS 
AANSOEK OM GOEDKEURING VIR EKSPERIMENTERING MET MENSE 
(5005 bygewerk in Augustus 1999) 
VERTROULIK 
(Volledig voltooide vorms in vyfvoud moet die sekretaris van die Etiekkomitee minstens een 
maand voor die aanvang van die eksperiment bereik. Projekte waar die navorser net 
bloedmonsters vir analise ontvang sonder dat hyself by die proefpersone betrokke is, moet 
steeds langs die gewone weg geregistreer word . Navorsers wat aan projekte deelneem wat 
by ander instansies se Etiekkomitees geregistreer is, moet hierdie komitee per brief van 
sodanige projekte in kennis stel en die komitee van 'n protokol voorsien.) 
Hierdie vorm is ook op rekenaarskyf in WinWord- en MSWord-formaat of via die PUK-
rekenaarnetwerk beskikbaar by F:lAppslAlginIIEtiekkomIMense.doc. Die jongste weergawe 
van die vorm, 5005 op die netwerk beskikbaar, moet gebruik word. 
Persoonlike besonderhede van projekleier/navorser 
1. Titel, voorletters en van: Mev W H Oldewage-Theron ........... ... ..... .. ... .... ..... .. .. ..... .. .. . 
2. Volledige kwalifikasies: B Sc Dieetkunde Honneurs, Nagraadse Diploma in Haspitaal 
Dieetkunde, M Sc ......... ... ..... .. .... ....... ..... ...... ....... .... ... ... ... ... ... .... .. .... ........................ . 
3. Rang/pas beklee: Hoof van Departement: Voedsel, Vaaldriehoek Technikon .... ..... . 
('n Volledige curriculum vitae moet aangeheg word deur aansoekers vir wie daar nie 
'n CV sentraa/ aan die PU vir CHO beskikbaar is nie asook deur aile eerste 
aansoekers moet so 'n CV een keer per jaar aanheg) . 
4. Skool (vakgroep)lInstituut: Skool vir Fisiologie, Voeding en Gesinsekologie ............ . 
5. Telefoon: (016) 950 9279 ..... ..... ..... (w) (016) 423 2660 ...... .. ............................. (h) 
6. PU Bussie: N V T .. .. .. .... ..................... ...... .... ..... ......... ...... ................... ..... ... ... .. ...... .. . 
Besonderhede van eksperiment 
1. Titel van projek/proef: 
Evaluation of the fortification of tea and sugar with vitamin A and iron ...................... . 
. 
2. Volle name, van, rang/pos en kwalifikasies van werklike toesighouer indien nie 
prajekleier/navarser self nie: 
3. Titels, voorletters, van en kwalifikasies van aile medewerkers: 
Me M Selepe, B Nutrition (US) .... ..... .. ......................................................... .............. . 
Me E Dicks B Huishaudkunde Hons ........ .. .......... .... ... .. . , .... .. .... .. ............... ...... ......... .. 
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4. Naam en adres van toesighoudende geneesheer: 
(In aile gevalle waar noodsituasies moontlik kan ontstaan, word die fisiese 
teenwoordigheid van 'n geneesheer en 'n geregistreerde verpleegkundige vereis. Vir 
die onltrekking van bloedmonsters by dieetmanipulering en derglike studies kan met 
die teenwoordigheid van 'n geregistreerde verpleegkundige volstaan word.) 
5. 8eoogde aanvangsdatum: 10 Januarie 2000 ................................... .. .. .. .. ................ . 
6 . Verwagte voltooiingsdatum: 1 Mei 2000 ............... .. ................ ..... ............. .... .... ........ . 
7. Plek waar eksperiment uitgevoer gaan word: 
(Aile prosedures waarby noodsituasies kan ontstaan, moet binne 'n noodsorgruimte 
wat deur die toesighoudende geneesheer goedgekeur is, uitgevoer word.) 
Vaaldriehoek Technikon ..................... ...... ........................ .... .. ................................... . 
8. Agtergrond: 
(Beskryf kortliks die behoefte wat tot die betrokke eksperimentering aanleiding gegee 
het. Ondersteun u voorlegging met relevante literatuurverwysings.) 
Kyk protokc:l aangeheg ... ................................................................................... ....... . 
9. Doelstelling : 
(Beskryf kortliks die doel wat met die proef nagestreef word) 
Kyk protokol .... .. .... ....... ... .... ..... ............. ... ... ........................................... .. ..... .•.... .•.... . 
10. Eksperimentele ontwerp en prosedures: 
(Beskryf volledig hoe die eksperiment uitgevoer gaan word en walter prosedures 
gebruik gaan word. Dui altematiewe prosedures aan, indien van toepassing, asook 
die statistiese beplanning. Indien daar van menslike weefsel of Iiggaamsv/oeistowwe 
gebruik gemaak gaan word beskryf hoe u hierdie materiaal gaan wegdoen.) 
Kyk protokol ......... .. .................... ................................ ......... ................... ................... . 
11 . Eksperimentele medisyne: 
(Gee die nodige besonderhede soos goedgekeurde naam, aanvaarde dosering, 
farmako/ogiese werking, ongewenste effekte, voorsorgmaatreels, teenaanwysings en 
ander relevante inligting, om die Etiekkomitee in sy beoordeling van die aansoek te 
help. In die geval van bekende middels kan na handboeke verwys word.) 
Geen .... .. ..... ... .... ..... ..... ... ........ .. ... ...... .... ... ... ..... .. .... .. .......... ...... .. .... ..... .. ... ............ .... . 
127 
© Central University of Technology, Free State
Annexure 1 
11 .1 Is bogenoemde medisyne geregistreer? NVT ...... .... .. .... .. ...... .......... .. .... .. .. .. .. ........ .. . 
11.2 Indien nie, is goedkeuring vir die gebruik van ongeregistreerde medisyne vanaf die 
Medisynebeheerraad verkry? NVT ................ .............. .. ... ... .. ..... .... .......................... . 
11 .3 Indien "Ja" by 2.11 .2 gee die datum van goedkeuring: 
(Finale goedkeuring van die aansoek deur die Etiekkomitee sal onderhewig wees aan 
goedkeuring van die proef deur die Medisynebeheerraad.) 
12. Instansies wat eksperimentering borg . 
(Gee, indien van toepassing, die naam en adres van aile instansies met 'n 
uiteensetting van die aard en omvang van die borgskap.) 
Vaaldriehoek Technikon Sentrale Navorsingskomitee ± R 20 000 
FRD (± R 40 000 aangevra) .. .... .......... .. ...... .. .... .... ...... .. .... .. ...... .. ...... ............ .. .... .... . . 
12.1 Ontvang enige van die ondersoekers direk of indirek persoonlike vergoeding van die 
borg? Indien wei, spesifiseer. 
Nee .. ... .................................... ........ ... .......... .. .... .. .... .. .... .. ... ... .......... ... ....... .... ... ........ . 
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Proefpersone 
1. Ingeligte toestemming 
Die vorm vir ingeligte toestemming (hierby aangeheg) moet volledig ingevul en 
gehanteer word volgens die MNR-Riglyne ten opsigte van Etiese Beginsels in 
Mediese Navorsing, Hersiene Uitgawe (1987), Aanhangsel V. 
Vir nie-terapeutiese eksperimentering op proefpersone onder die ouderdom van 21 
jaar is die skriftelike toestemming van sy/haar ouer of wettige voog nodig. 
2. Ontvang die proefpersone vergoeding, en indien wei, hoeveel? 
Vervoer onkostes sal verhaal word, ± R 10 per persoon per dag ....... ..... .................. . 
(U aandag word pertinent gevestig op by/ae 5 van die Etiekkomitee se rig/yne vir 
Eksperimentering met Mense en Diere, September 1988.) 
3. Word studente as proefpersone gebruik? Ja, slegs 25 van die totale steekproef van 
60 is studente by die Technikon ..... ................................ ........................................... . 
(Studente mag nie individuee/ am dee/name genader word nie en dee/nemende 
studente moet verkieslik nie by die projek/eier of sy medewerkers 'n kursus vo/g nie.) 
Risikoversekering 
1. Deur walter versekering word die risiko verbonde aan hierdie projek gedek? Gee 
volledige besonderhede. 
Lae risiko projek. 'n Geregistreerde, ervare verpleegsuster (W. Rademan ) trek 5 ml 
volbloed (EDTA) en 20 ml serum per keer ............................ ................................... .. 
2. Is die versekering voldoende? 
Ja ............ .......... ....... .. ........ .. ... .. ... ... .. ... ....... ... ... .... ...... .. .... ...... .... ..... ... .......... ... ......... . 
Aansoek en verklarings 
1. Projekleier: 
Hiermee doen ek, die ondergetekende, aansoek om die uitvoering van die 
eksperiment 5005 beskryf in die voorafgaande protokol en verklaar dat: 
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1.1.1 ek my deeglik vergewis het van die inhoud van 1) die Etiekkomitee se Riglyne vir die 
Eksperimentering met Mense en Diere (September 1988) en 2) die Mediese 
Navorsingsraad se Etiese Beginsels in Mediese Navorsing, Hersiene Uitgawe (1987) 
[dit is elektronies beskikbaar op die Pukweb by F:\Apps\AlginIIEtiekkom] en dat ek 
my by die riglyne soos vervat in hierdie twee dokumente sal hou; 
1.1.2 ek elke proefpersoon wat aan die eksperiment deelneem, die meegaande vorm vir 
ingeligte toestemming sal laat onderteken en die skriftelike toestemming van die 
ouers of wettige voogde van aile minderjarige proefpersone sal verkry voordat die 
eksperiment 'n aanvang neem; 
1.1 .3 die inligting in hierdie aansoek na my beste wete juis is en dat geen etiese kodes met 
die proef geskend sal word nie; 
1.1.4 ek nie van die goedgekeurde protokol sal afwyk nie; 
1.1.5 aile vooraf-navorsing ter uitvoering van die proef volledig afgehandel is, en dat ek 
myself geskik en bekwaam ag om die navorsingswerk te doen en 
1.1.6 ek jaarliks op die voorgeskrewe vorm aan die Etiekkomitee sal verslag doen 
aangaande etiese aspekte van die projek. 
Volle name: 
WilhelminaHendrikaOldewageTheron ......... ......... ..... .. .... ...... .... .... .. ... ...... ..... .. .... .. ..... .... ........ . 
Handtekening: .... ... .. .. ...... ......... .... .. .... .. .. ... ... ... Datum:8 November 
1999 ... .... ... .. .... .. ... .. ... .... ..... ..... ... ...... ..... ... . 
2. Toesighoudende geneesheer 
Die Etiekkomitee steun volkome op die professionele oordeel van die toesighoudende 
geneesheer met be trekking tot die aard en omvang van toesighouding asook die 
graad van risiko van elke projek. 
2.1 Wat behoort na u mening die aard en omvang van toesighouding tydens die projek te 
wees? 
2.2 Wat is na u mening die graad van risiko vir die proefpersone betrokke by die projek? 
Let wei: Reelings ter voldoening aan die toesigvereistes moet onderling tussen die 
geneesheer en die projekleier getref word. 
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2.3 Ondertekening van die protokol impliseer: 
(a) dat u u voor die aanvang van die projek sal vergewis van die mediese geskiktheid 
van elke proefpersoon, en 
(b) dat 'n mediese leer (waar u dit nodig ag) vir elke proefpersoon aangehou sal word en 
. (c) dat u volledig op hoogte van die risiko verbonde aan die projek sal wees. 
Volle name: .. .. .... .. ....... .. ..... ................... .................. ...... ...... .. .... ...... ...... .................. .......... .... . 
Handtekening: .............. ...... ...... ..... .. .... ... .. Datum: .... ...... ...... ..... ..... ............... .......... .......... ... . 
3. Skooldirekteur/lnstituutdirekteur en Fokusareadirekteur: 
Hiermee verklaar ek dat bogenoemde projek wetenskaplik verantwoord is, dat 
eksperimentering mag voortgaan indien dit deur die Etiekkomitee goedgekeur word 
en dat die projekleier/navorser oor genoegsame fisiese geriewe, toerusting en geld 
beskik om die proef uit te voer en te voltooi. 
Skooldi rekteu rll nstitu utd i rekte ur: 
Volle name: ... .... ... .. ...... ..... ............. ....... ... .. , ......... ........ , ..... .. ............ ..... ... .. .... .. .... ...... .. .. ... ... . . 
Handtekening: ....... ..... .. .... .... .................... Datum: ......... .. .......... .. .... .... ... .... ... ......... ....... ... ... . 
Fokusareadirekteur: 
Volle name: ........... .... ... .. .. ...... ...... ... .... .. ....................................... .................... .. ................... . 
Handtekening: .......................... .. .. .... ..... ... Datum: .. .... ........ ................... .. .... .......... ............. .. 
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Vorm vir ingeligte toestemming 
DEEL 1 
VERTROULIK 
. 1. Skool (vakgroep)lInstituut: 
2. Titel van projek/proef: ... ...... .. .... ...... ..... .. ... ...... ... .... ... ... .. .. .... ..... .... ... .... ... .. ..... .. .. ... .. . 
3. Volle name, van en kwalifikasies van projekleier/navorser: 
4. Rang/pos van projekleier/navorser: 
(bv. Professor, Lektor, Navorsingswetenskaplike ens . .) 
5. Volle name, van en kwalifikasies van persoon wat met die daadwerklike toesig oor 
die projek/proef bel as sal wees: 
(Voltooi slegs as dit iemand anders is as die persoon in 4 hierbo genoem) 
6. Naam en adres van toesighoudende geneesheer (waar van toepassing): 
7. Die doel van die projek/proef: 
... ... .. .. .. ...................... ................ . , ..... ...... ..... .. .. .. ... ..... ...... ........ .... ....... . ...... .... .. .... ..... . . 
8. Verduideliking van die aard van aile prosedures wat gevolg sal word, insluitende 
identifisering van nuwe prosedures: 
9. Beskrywing van die aard van die ongerief of gevare of waarskynlike permanente 
nagevolge vir proefpersone wat met die projek/proef gepaard mag gaan: 
(lnsluitende moontlike newe-effekte van en interaksies tussen geneesmiddels asook 
radio-aktiewe isotope wat gebruik sal word.) 
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10. Voorsorg wat getref word om proefpersone te beskerm: 
11 . 8eskrywing van die voordele wat uit die resultate van die proef verwag kan word: 
12. Alternatiewe prosedures wat voordele vir die proefpersoon sal inhou: 
(Voltooi s/egs indien op die bepaa/de projek van toepassing.) 
Handtekening: .......................................... Datum: .......... .. ............. .. .. .. ..... ...... ... .. ....... ... .. ... . . 
Projekleier 
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DEEL 2 
Aan die ondertekenaar van die toestemming vervat in deel 3 van hierdie dokument: 
U word uitgenooi om deel te neem aan die navorsingsprojek/proef soos genoem in 
paragraaf 2 van Deel 1 hiervan. Dit is belangrik dat u die volgende algemene beginsels, 
wat op aile deelnemers aan ons navorsingsprojekte van toe passing is, sal lees en verstaan : 
1. Deelname aan die projek/proef is heeltemal vrywillig . 
. 2. Dit is moontlik dat u persoonlik nie enige voordeel uit u deelname aan die 
projek/proef sal trek nie, alhoewel die kennis wat deur middel van die projek/proef 
opgedoen mag word andere tot voordeel kan strek. 
3. Dit staan u vry om uself te enige tyd sonder opgawe van redes aan die projek/proef 
te onttrek. U word egter vriendelik versoek om nie sonder deeglike besinning aan 
die projek/proef te onttrek nie, aangesien dit o.a. die statistiese betroubaarheid van 
die projek/proef nadelig mag bernvloed. 
4. 'n Samevatting van die aard van die projek/proef, die vermeende risikofaktore, 
faktore wat moontlik ongerief of ongemak vir u kan veroorsaak, die voordele wat 
verwag kan word en die bekende en/of waarskynlike permanente nagevolge wat u 
deelname aan die projek/proef op u proefpersoon mag he, word in Deel 1 hiervan vir 
u uiteengesit. 
5. U word aangemoedig om op enige stadium enige vrae wat u in verband met die 
projek/proef en die prosedures in verband daarmee mag he aan die projekleier of sy 
personeel te stel, wat u navrae graag sal beantwoord. Hulle sal ook die projek/proef 
volledig met u bespreek. 
6. Indien u minderjarig is, is die skriftelike toestemming van u ouer of wettige voog 
nodig alvorens u aan hierdie projek mag deelneem. 
7. U word daarop gewys dat van u vereis word om die Universiteit te vrywaar teen 
aanspreeklikheid weens benadeling wat as gevolg van die handelinge van die 
Universiteit of enige van sy werknemers of studente of ander proefpersone vir u of 
iemand anders mag ontstaan. Voorts dat u die Universiteit skadeloos moet stel in 
geval van enige aanspreeklikheid wat die Universiteit teenoor enigiemand mag 
oploop weens benadeling van uself of 'n ander deur of as gevolg van u deelname 
aan die projek/proef in Deel 1 hiervan uiteengesit. Laastens word van u vereis om 
afstand te doen van enige aanspraak wat u teen die Universiteit mag verkry as 
gevolg van benadeling van u of iemand anders, weens u deelname aan die 
projek/proef in Deel 1 uiteengesit. 
8. Indien u getroud is, word van u eggenooUe vereis om afstand te doen van enige eise 
wat hy/sy andersins teen die Universiteit sou kon he as gevolg van enige benadeling 
of die dood van u weens die projek/proef in Deel 1 uiteengesit. 
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DEEL 3 
Toestemming 
Titel van projek: 
Ek, die ondergetekende ... .. ........ .. ... .... .. ... .......... ...... .. .... .. .. .... . ... .. . (volle name) 
het die voorafgaande gegewens in verband met die projek/proef genoem in DEEL 1 en 
DEEL 2 hiervan gelees en ook die mondelinge weergawe daarvan aangehoor en ek verklaar 
dat ek dit verstaan. Ek was die geleentheid gegun om tersaaklike aspekte van die 
projeklproef met die projekleier te bespreek en ek verklaar hiermee dat ek vrywillig aan die 
projeklproef deelneem. Ek gee hiermee my toestemming om as proefpersoon in 
bogenoemde projek op te tree. 
Ek vrywaar hiermee die Universiteit asook enige werknemer of student van die Universiteit, 
teen enige aanspreeklikheid wat teenoor my, in die loop van die projeklproef mag ontstaan. 
Ek onderneem verder om geen eise teen die Universiteit in te stel weens skade of 
persoonlikheidsnadeel wat ek weens die projek/proef mag Iy nie, hetsy dit aan die 
nalatigheid van die Universiteit, sy werknemers of studente, of ander proefpersone mag 
onstaan nie. 
(Handtekening van proefpersoon) 
Onderteken te ......... ...... " .... ..................... op 
GETUIES 
1. . ........ " .... .. .... ..... ................ ... ........ ........ . 
2 .. ...... " .... .. .......... ...... ..... ...... " .... ...... .. .... " 
Onderteken te .. ..... .... ... " ... . " ......... " .... ..... op .... .... .. ... .. ..... . ........ . 
Vir nie-terapeutiese eksperimentering op proefpersone onder die ouderdom van 21 jaar is 
die skriftelike toestemming van die ouer of wettige voog nodig. 
Hiermee gee ek ... ... ..... .... ..... . ...................... .. .... .. ..... . .. . ..... . .. .. .. .... . (volle name) 
ouer of wettige voog van die proefpersoon hierbo genoem toestemming dat hy/sy aan 
hierdie projeklproef mag deelneem en ek vrywaar hiermee die Universiteit asook enige 
werknemer of student van die Universiteit, teen enige aanspreeklikheid wat teenoor my in 
die loop van die projeklproef mag ontstaan. 
Handtekening: ... ... .. ..... ..... .......... .......... .... Datum: 
Verwantskap: .. . ... ... ................... . 
Vir eksperimentering op getroude proefpersone is die onderstaande vrywaring deur die 
eggenooU-e nodig : 
Hiermee onderneem ek, .. .......... ... ........ .. .............. ....... ...... ............. .. ............... (volle name) , 
die eggenoot/-e van die proefpersoon in hierdie aansoek, om geen eis teen die Universiteit 
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in te stel vir behandeling weens besering, skade of die dood van die gemelde persoon as 
gevolg van die projeklproef in hierdie aansoek uiteengesit nie, hetsy sodanige besering , 
skade of dood veroorsaak is deur die nalatigheid van die Universiteit, sy personeel of sy 
studente of 'n ander proefpersoon, of op enige ander wyse. 
Handtekening: ........ ................. ............... .. Datum: 
Verwantskap: ...... .. .................. . 
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INFORMED CONSENT: EVALUATION OF THE FORTIFICATION OF 
SUGAR WITH VITAMIN A 
I, the undersigned . .. ....... .. .... .................................. .. ......... (full names in print) have read the 
details of the project, or have listened to the oral explanation thereof, and declare that I understand iLl have 
had the opportunity to discuss relevant aspects with the researcher and declare that I voluntarily participate 
in the proj ect. I hereby give consent to participate in the project and that blood samples may be taken from 
me. 
I hereby indemnify the Technikon, or any employee of the Technikon, against any liability that may 
originate during my participation in this research project. I further undertake that I will not lay any claim 
against the Technikon or any Technikon employee for damage or personal disadvantages that I may suffer 
as a result of this research. 
Signature of volunteer 
Signed at .. ..... ..................... . ... . . . .. ..... ..... . ... on ..... ... .... . ....... . .. I I ...... .. ............. .. .. ... . . ... . 
Witnesses 
Name ..... .............. ... ..... ............... . . Name ..... ..... ... ..................... .. . ..... . .... . ..... . 
Signature .. . ' ........ . . .. .............. ....... . . Signature ................ ......... , ... ... ... ... ....... , .. .. 
Signed at ...... . .......... .. .. ..... .... .. ...... .. ..... . .... . on ... ..... ... .. ....... . ... .... . ...... ....................... . 
For subjects under the age of21 years, signed consent of a parent or legal guardian is essential. 
I, ........ ............ ............................................. . .. ....... ... .... . (full names), the parent/legal 
guardian of the person named above, hereby consent that she may participate in this research project and 
that blood samples may be taken from my child . 
I hereby indemnify the Technikon, or any employee of the Technikon, against any li ability that may 
originate during her participati on in this research project. I further undertake that I wi ll not lay any claim 
against the Technikon or any Technikon employee for damage or personal disadvantages that my child may 
suffer as a result of this research. 
Signature .. .. .................... .. .. ...... .... . Relationship ......... .•. , .. .. ... .. . ...... .•....... .. ......... 
Signed at ...... ...... .......... .. ........ •.... .. .... .• ...... on ... ... ....................... ... .... . ...... .. ... ............ . 
Address of volunteer: .. .... .... .. ..•.. .•...•.. .•.. .... .... .. .. ..... ....... •........•.. .. ... . ........•......... ... ...... ... 
.... ..................... ................... .... .......................... ............ ..... ........ .... .... ....... .. ......... .. .. 
..... ..... ........ .. ........... .... ... .... ....... .. ... .... .... ... .... ................ ..... .. ...... .. ............ ................. 
Telephone number : ..... . .. . ......... .. .... . ... .. ... ... .. ... ... . .......... ...... .. ........ . .. . .... . . 
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Request For Analysis 
Date Received: March 1, 2000 Reference no: F 00-{)31 
Requested For. Sugar Fortification Requested By: H Robertson 
Product: Sugar 
Batch I Ref Number Analyze For Declared Level Results Found 
Wamin A Sugar 2 VrtaminA. 80 IU / 9 1431U I 9 March 
SugarCSIR VrtaminA 7.17IU/g 9.4IU I 9 
Date Completed: March 3, 2000 
Analyst M Kent 
These results 819 19ported in s/Jict confidence and wII~ 
Roche Products (Ply) Ud. 
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Request For Analysis 
Date Received: 
Requested For: 
Batch / Ref 
Number 
17.Feb 
02.Mar 
28 March top 
28 March bottom 
April 2, 2000 
Sugar Fortification 
Project 
Analyze For 
VilaminA 
Vitamin A 
VrtaminA 
Vitamin A 
Date Completed: April 12, 2000 
Analyst: M Kent 
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SUGAR INFORMATION 
Please use our sugar 
Do not give the sugar away 
Do not sell the sugar 
We will know if you use our sugar through blood analysis 
All the persons living with you in the house may use our sugar 
Please do not use more sugar than you would normally use 
Use the sugar in all the food you normally use sugar in 
If you cook food usually with sugar, use our sugar to cook with 
It is important that you keep the sugar in the purple bag at all times 
Close the bag each time after opening 
We prefer that the sugar is stored in the purple bag in another container with a lid. 
Do not store the sugar on the floor 
Keep the sugar away from wet places 
Store the sugar away from sunlight 
We give enough sugar to be use in four week 
Try not to drink tee with your meals, but rather in between the meals 
Do not use non-calorie sweeteners e.g. Nutrasweet 
Use the sugar when you bake cakes 
Brush your teeth regularly to prevent dental caries 
Do not use more sugar than normally to avoid obesity 
Use sugar in moderation 
If you are not sure of the correct use of the sugar please contact Mrs. Selepe at (016-950 
9460) 
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EVALUATION OF THE FORTIFICATION OF SUGAR WITH 
VITAMIN A 
INSTRUCTION MANUAL 
IMPORTANT 
DO NOT START SAMPLING BEFORE YOU HAVE READ 
AND UNDERSTOOD THE FOLLOWING INSTRUCTIONS 
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1 IMPORTANCE OF THE STUDY 
In children three micronutrient deficiencies, namely vitamin A, iron and iodine, are 
considered to be a major health problem in developing countries. These are presently 
receiving high priority globally. Communities that are affected the most are those in 
situations where poverty, unemployment, civil unrest, war and exploitation remain 
endemic (SAVACG, 1995: 39; USAID, 1993: 2) . World wide more than 250 million 
young children and many of their mothers are vitamin A deficient, increasing the severity 
of common illnesses and their risk of death. Vitamin A is a powerful "child survival 
tool" , reducing child mortality by 23-34 % (Malanick, 1999: 1). 
Growth retardation, brain damage, diminished cognitive function and diminished working 
capacity in children and adults, as well as increased susceptibility to and severity of 
infections, and mortality are the collective result of these micronutrient deficiencies 
(SAVACG, 1995: 39; USAID, 1993: 2). 
A new concept is emerging in terms of micronutrient deficiencies. At a national level the 
constraints to make more vitamins and minerals available to the population can be largely 
addressed by implementing programmes designed to educate people. These could be 
diversifying their diets 6r by fortifying commonly eaten foods with the missing 
micronutrients or providing nutrient supplements through targeted distribution programmes 
(USAID, 1993: 7). 
Many studies have been done to determine the effect of vitamin A supplementation on 
nutritional status of people. The purpose of this study is to determine the effect of fortified 
vitamin A on the nutritional status. Although a number of similar studies have been done in 
other countries, this is the first study in South Africa where vitamin A fortified sugar will be 
used. The results of this study will be published in national and international academic 
journals and also be presented at nutrition conferences as this will assist the policy makers 
on the effectiveness of fortification and the decision for a suitable vehicle for vitamin A 
fortification in South Africa. 
The team leaders of this project are Ms W Oldewage-Theron, Ms E Dicks and Ms M 
Selepe. In order to ensure accurate and reliable data, the team leaders will supervise the 
data collection process and cross-check some of the information that you as field worker 
has obtained. If differences are found, you will be asked to repeat the observations in the 
presence of one of the team leaders in order to find the reasons for the differences. 
All questions must be asked in the same way by all the field workers. Should questions 
be translated, please ensure that the meaning of the question is not changed by the way 
the question is rephrased. The team leaders will be available for assistance at all times 
during the trial. 
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2 EQUIPMENT PER TEAM 
The following equipment must be prepared and be available for the week that 
measurements will be done . 
2.1 Team 1 Station 1 
• All the subject files 
• 100 X Demography questionnaires 
• 100 X Consent form 
• Check lists 
• 10 X Pens 
2.2 Team 2 Station 2 
• 2 X Measuring tape 
• 2 X Scales 
• 2 X Pens 
• Calculator 
2.3 Team 3 Station 3 
• 100 X QFFQ's 
• 100 X Food diary questionnaire 
• 100 X Sugar consumption questionnaire 
• 100 X KAB questionnaire 
• ' 100 X Compliance questionnaire 
• 10 X Pens 
2.4 Team 4 Station 4 
• I X Blood pressure equipment 
• 5 X Thermometers 
• 20 X Pairs of surgical gloves (medium size) 
• \00 X Green butterflies (21G) 
• 100 X Webcol sterile preps 
• 100 X syringe needles 
• 100 X 5 ml Disposable syringes 
• 100 X Elastoplast plasters 
• Disinfectant 
• 100 X Vacutainers 
• 100 X 5 ml EDT A tubes (purple rubber top) contained in polystyrene trays as 
supplied by the manufacturers 
• 100 X 10 ml plain tubes (red rubber top) contained in polystyrene trays as 
supplied by the manufacturers 
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• I X pack of cotton wool (I kg) 
• 5 X Black plastic sheets (50 X 50 cm) 
• 5 X Roller paper towels 
• 4 X Cooler boxes with 3 ice packs each 
• I X Waste disposal unit 
• Pens 
2.5 Team 5 Station 5 
• Fruit juice 
• Bread 
• Spreads 
• Knives 
• Paper plates 
• Paper serviettes 
• Pen 
2.6 Team 6 Station 6 
• Training manual 
• Flip chart 
• Pens 
2.7 Team 7 Station 7 
• Fortified sugar 
• Unfortified sugar 
• Pens 
3 INSTRUCTIONS TO FIELD WORKERS 
Each team consists of two people, except team 3 consisting of 4 people. 
3.1 Team 1 Station 1 
At the beginning: 
• Explain the routine for the day 
• Register the subject on the attendance register as being present 
• Complete the demography form (week I only) 
• Ensure that the consent form is in the file (week I only) 
At the end: 
• Check that the station form is complete 
• Collect the completed file from the subject 
• Sign the subject out on the register 
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• Pay each subject RIO for her expenses. Each subject must complete the claim 
form and sign for receipt of the money (weeks 0, I ,4,8) 
• Pay each subject R 60 for her expenses. Each subject must complete the claim 
form and sign for receipt of the money (week 12) 
3.2 Team 2 Station 2 (weeks 1,4,8,12) 
Weight measurement: 
• Place the scale on an uneven uncarpeted area. Ensure that the spirit level 
indication is in the middle. 
• Switch the scale on and wait for the zero indication (0.0) as well as the stable 
indicator CO in the top left-hand corner of the display panel) to appear. 
• Weigh the subjects with clothes, without shoes, after emptying their bladders 
• Place the subject on the scale. They must stand upright in the middle of the 
platform, facing the fieldworker and looking straight ahead. Their feet must be 
flat and sl ightly apart. They must stand still until the measurement was recorded 
in the space provided on the station card. 
• Let the subject step down from the scale and wait for the zero reading to appear 
on the digital display. 
• Repeat the procedure. The reading should be within I OOg of each other. 
Height measurement: 
• The subject must remove her shoes. 
• Position the subjcct as follows: 
facing the field worker 
shoulders relaxed, with shoulder blades, buttocks and heels touching the 
measuring board 
arms relaxed at the sides 
legs straight and knees together 
feet flat, heels touching 
• The subject must look right ahead before the headpiece is slid down on the head. 
It should just touch the crown of the head. 
• Record the reading in mm on the space provided on the station card. 
• Repeat the procedure. The two readings should not vary by more than 5 mm. 
Waist measurement: 
• Position the subject as follows: 
facing the fieldworker 
standing erect with the abdomen relaxed, arms at the sides and feet together 
• Place an inelastic tape around the subject, in a horizontal plane, at the level of the 
natural waist, which is the narrowest part of the torso 
• Record the reading in mm on the space provided on the station card. 
• Repeat the procedure. The two readings should not vary by more than 15 mm. 
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Hip circumference: 
• Position the subject as follows: 
facing the fieldworker 
standing erect with the abdomen relaxed 
arms at the sides 
feet together 
no tensing of the gluteal muscles 
• Stand at the side of the subject to ensure the tape is held in a horizontal plane 
• Place an inelastic tape around the subject, in a horizontal plane, at the level of the 
greatest posterior protuberance of the buttocks, which usually corresponds 
anteriorly to about the level of the symphysis pubis. 
• Record the reading in mm on the space provided on the station card. 
• Repeat the procedure. The two readings should not vary by more than 15 mm. 
Waist hip ratio: 
• Calculate the body mass index by using the following formula: 
Body weight = 
Square Body height 
• Record the BMI on the station card. 
3.3 Team 3 Station 3 
• Complete the QFFQ (weeks 0,1,4,8,12 -fieldworker 1) 
• Hand out the food diary and explain completion (weeks 0,1,4,8- fieldworker 2) 
• Complete the sugar consumption questionnaire (weeks 0, 8 - fieldworker 3) 
• Complete the KAB questionnaire (weeks 0, 4, 12 - fieldworker 4) 
• Complete the compliance questionnaire (week 12 - fieldworker 2) 
3.4 Team 4 Station 4 
Instructions for blood sampling: 
• Ensure that the informed consent form has the authoritative signature 
• Put on two pflirs of surgical gloves. 
• Take 20 ml blood from each subject. 
• Write clearly on three labels the subject number and date of sampling. 
• Retrieve sample tubes from the cooler box, replace lid and keep cooler box closed 
at all times. 
• For each subject, select on tube with a purple rubber top, one with a blue rubber 
top and one with a yellow rubber top. Stick labels (one on each tube) directly over 
label already on tube. 
• Slowly and carefully draw 20 ml sample of venous blood into the syringe using a 
butterfly. 
• Write the time of sampling on the tube labels. 
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• Slowly and carefully transfer from the syringe I ml of the sampled blood into the 
tube with the purple rubber tube and the remaining blood into the tube with the 
red rubber top by piercing the rubber seals with the butterfly needle. 
• Gently and repeatedly (5 X) invert both tubes. Do not shake. 
• Place tubes in polystyrene trays. Keep tubes shielded from direct light or sunlight 
by covering the trays with the black plastic sheets. 
• All blood samples drawn must be returned to the cooler box within two hours 
from the time the blood sample was drawn. 
• Dispose of the syringe and butterfly in waste disposal unit. 
• Proceed with the next subject by repeating the previous steps until the complete 
blood sample has been obtained from all the subjects. 
• Dispose of the surgical gloves in the waste disposal unit and seal. 
• Check that all the samples are complete and the details on the labels are complete. 
• Close the cooler box and remove to the laboratory with the waste disposal unit. 
3.5 Team 5 Station 5 
• Check that the subject has completed all the steps in stations one to four by 
checking the station card. 
• Hand out a sandwich with a 250 ml fruit juice to each subject and sigh the station 
card. 
3.6 Team 6 Station 6 
• Group 5 subjects together. 
• Hand out a training manual to each of the subjects. 
• Read and explain the training manual. Answer all questions and call a team leader 
should you not be able to answer the questions. 
• Sign the station card for each subject. 
3.7 Team 7 Station 7 
• Check that the subject has completed all the steps in stations one to six by 
checking the station card 
• Check the code on the subject file and issue the sugar accordingly 
• NOO 1, N 095, etc = sugar bags marked with an "N" 
• F020, F085 = sugar bags marked with an "F" 
• Sign the station card 
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~ VITAMIN A FORTIFICATION PROJECT 
Subject name: Subject number:. __________ _ 
STATIONS ACTNITY CHECK CHECK CHECK CHECK CHECK 
WEEK 0 WEEK I WEEK 4 WEEKS WEEK 12 
Station 1 Recruinnent (Date) 
Check/control 
Demography questionnaire - - - . - -
.-
3b~ , 
'''' -Consent form - - 7 -
-
.;';. _. 
-
,D. " 
-
y C. __ 
Station 2 Weight . --" kg kg kg kg 
Antropometry 
, 
-
Height -
.... 
m m m m , 
Waist ; ;;j;~.~~~ .. ;:i:{~~,~~~.< . .; '-~- em em em em 
Hip circumference • "!""". - em em em em 
Waist Hip Ratio - em em em em 
~- . 
Station 3 QFFQ 
Questionnaires 
Food Diary Out In Out In Out In Out In 
Sugar consumption 
~- .'- '. ,,-
KAB 2X 
" 
, : 
. -
-
if .;.. _ ;n; 
Compliance ~ ~ '''~. -,&lv' - . -
-
;;c' 'V ., '"". .-
.~ .~ 
Station 4 Blood pressure mrnHg mmHg mmHg mmHg mmHg 
Clinical signs and Oral temperature ' C 'C 'C 'C 'C blood samples 
Vitamin A 
Citrate (5ml EDTAl 
Full blood (20mJl 
Station 5 Snacks 
Cafe 
Station 6 Training session 
Education proerarn 
Station 7 Issuing of sugar -'-'+ ...... , , ':':'.' .' I'" ,l{:l, :'~ ~ , 
Store .. ~ ~ _. ~ 
Station I Back to check/control 
Check/control (Si~ completed fonm) 
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HEALTH QUESTIONNAIRE: EV ALUA TION OF THE 
FORTIFICATION OF SUGAR WITH VITAMIN A 
A I Surname lID number 
Age 
B 
ARE YOU SUFFERING OR YES NO IF ANY ANSWER IS YES, 
HAVE YOU SUFFERED GIVE DETAILS OF THE 
FROM NATURE, SEVERITY AND 
DURATION OF ILLNESS 
1. Any skin disease? 
2. Any affection of the skeleton 
and/or ioints? 
3. Any affection of the eyes, 
ears nose or teeth? 
4. Any affection of the heart or 
circulatory system? 
5. Any affection of the chest or 
respiratory system? 
6. Any affection of the digestive 
system? 
7. Any affection of the urinary 
system and/or genital organs? 
8. Any nervous affection or 
mental abnormal ity? 
9. Any other illness? 
c 
YES NO 
I. Do you suffer from any defect of hearing, speech or sight? 
2. Are you physically disabled and do you use artificial limbs? 
GIVE DETAILS OF THE NATURE AND SEVERITY OF 
THE DISABILITY 
... ..... . ............. ... .... . ........ . . .. .... . ........... .... . ...... ...... 
..... . . ........ ............ ............... ........ . ...... .................. 
........ . .............. . ....... ........................ . ......... . ..... .. .. 
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D 
Have you undergone any operations? 
GIVE DETAILS OF THE NATURE AND DATE OF THE 
OPERA TION/S 
E 
YES NO 
I declare that the above-mentioned information is true and correct and that I have not 
withheld any information regarding my health. 
Signature . ... .. . . . ........ . .... . . ......... .... .......... Date .. . .................. . . ............ . ....... . 
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MEDICATION QUESTIONNAIRE: EVALUATION OF THE 
FORTIFICATION OF SUGAR WITH VITAMIN A 
A I Surname I 
First Names 
I ID number 
Age 
B 
I. Do YOU use any medication? 
2. If no go to section C. 
3. If yes, what for/why? 
4. What is the name of the medication you are 
taking? 
5. What is the dosage and how often do you 
take this medication? 
c 
Yes 
Dosage 
No 
How often? 
I declare that the above-mentioned information is true and correct and that I have not 
withheld any information regarding my medication usage. 
Signature ....... .. ..... . ......... ............... .. . .. ... Date ........................................... . 
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Subject number-,-, __ _ Interviewer __ -'-'--__ -'-__ _ 
QUANTITATIVE FOOD FREQUENCY QUESTIONNAIRE 
INTRODUCTION: 
Greeting 
Thank you for giving up your time to participate in this study, I hope you are enjoying it so far. 
Here we want to find out what people living in this area eat and drink, This information is 
important to know as it will tell us if people are eating enough and if they are healthy, 
Please think carefully about the food and drink you have consumed during the past four weeks, 
will now go through a list of foods and drinks with you and I would like you to tell me: 
• if you eat the food 
• how the food is prepared 
• how much of the food you eat at a time 
• how many times a day you eat it and if you do not eat it every day, how many times a week or 
a month you eat it. 
To help you to describe the amount of a food you eat, I will show you pictures of different 
, amounts of the food. Please say which picture is the <!Iosest to the amount you eat, or if it is 
smaller, between sizes or bigger than the pictures, 
THERE ARE NO RIGHT OR WRONG ANSWERS. 
EVERYTIllNG YOU TELL ME IS CONFIDENTIAL. ONLY YOUR SUBJECT NUMBER 
APPEARS ON THE FORM. 
IS THERE ANYTHING YOU WANT TO ASK NOW? 
ARE YOU WILLING TO GO ON WITH THE QUESTIONS? 
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FOOD 
Milk drinks 
Brand 
Yoghurt 
Squash 
Other speciCr 
DESCRIPTION 
SweetO 
SixO 
OroslLccoJ with sugar 
KooJ Aid 
Other 
- artilicial sweetener 
SNACKS AND SWEETS: 
Raw 
Amount 
Per 
155 
Per 
EATEN 
Per 
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INSTRUCTION 
Circle the subject's answer. Fill in the amount and times eaten in the appropriate columns. 
I shall now ask you about the type and the amount oHood you have been eating in the last few months. Please 
tell if you eat the food, how much you eat and how often you eat it. We shall start with maize meal porridge. 
Do you eat maize meal porridge? IYES II INO 12 
If YES, what type do you have at home now? 
Brand name 
Don't know 2 
Grind self 3 
Ifbrand name given, do you usually use this brand IYES I I INO 12 IDON'T KNOW I 3 
Where do you get your maize-meal from? (May answer more than oney 
Shop 0 
Employer 0 2 
Harvest and grind self 0 3 
Other - specify 0 4 
Don't know 0 ) 
FOOD DESCRIPTION Amount 
M.iu-mell Stiif(pap) 
Maize·meal Soft (slappap) 
Maize-meal Crumblv (phutu) 
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Brukf.st cereals Brand names of cereals at home 
no,",': (5 ) 
Do you pour mill;. on your poni6ge or cereal? 
Amount 
If YES, what type of milk (whole fresh. sour, I %, fat free, milk blend. ) ___ -'-______ _ 
Do you pour sugar on your cereaVponidgelrnBbclla 
Samp and 
Rice 
Pastas 
Ate the amounts of samp and beans the same as in the p'iclure? 
AIe the: amounts of samp And peanuts the same as in the picture? 
If no, do you use more peanuts than in the picture or Jess? 
White 
Brown 
157 
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You are being very h.lpfu\. Can I now Ilk you ahout meat? 
CHICKEN, MEAT, FISH 
FOOD DESCRIPTION Amount EATEN 
Per Per Per 
week month 
Chick.n i..:!B~oi!!:led~ ______ + __ -t __ -t __ -+ __ -+ __ _ 
Fried: in batter/crumbs 
Not coated 
Do you eat chicken skin ALWAYS II 
Chicken hon •• 
Red meat: 
Redm .. t 
BedOllai 
How do you like meat? 
With fat 
Whit vegetables are usually put into meat Slews? 
Cold meat. 
Canned meat 
SOMETIMES 1 I NEVER I ) 
158 
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FOOD DESCRIPTION 
Dried beanl/petsl Soup 
Soya producll .g. BllIIlds at horne now (5) 
Toppers 
Don't know 
Pilchard. in 
WE NOW COME TO VEGETABLES AND FRUIT 
FOOD DESCRIPTION 
Cabbage 
Amount TIMES EATEN 
Amount 
159 
© Central University of Technology, Free State
Annexure lU 
FOOD DESCRIPTION 
Spinach/morogol How do you cook spinach? 
other green leafy 
Other: 
Tomato Ind onion Home made· with rat 
'gray)" 
PumpkJD 
Carrots 
MeaJles/Sweet 
<om 
Beetroot salad 
Amount 
16160 
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FOOD 
Potatoel 
S"eet pot'toel 
Salad "egttables 
Of her vegetables, 
specify: 
Do you like fruit? 
Salad 
Other: 
DESCRIPTION 
How do you cook sweel 
AppJes/Pcars Fresh 
Amount 
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FOOD DESCRIPTION Amount 
Guaval 
If subject eats C4Med fruit: Do you have custard with canned fruit: 
Cultud Home made 
Wild fultlberriH Spctiry type 
Dried fruit Types: 
01bu fruit 
BREAD AIID BREAD SPREADS 
Bread/Bread rolls 
Do you spread an~thlng on the bread? 
Margarine What brand do you have at 
home now? 
DOn't know __ _ 
EATEN 
~I INO 12 
I SOMETIMES 12 
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FOOD DESCRIPTION 
Cheele Type: 
Other 'prelds: Specify 
MayoDoliwsalad Number of spoons, ___ _ 
DRINKS: 
SUllar/cu.p tta or 
MU,",cup lea or 
coffee 
MUkaI such 
What type of mBk do you use in 
Whole milk powder 
What type of milk do you drink 
Amount 
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FOOD 
Peanuts and 
Biscuits 
Cakes & tarts 
Sal'ouries 
DESCRIPTION 
Type 
Type 
Sausage rolls 
Samoosas 
Biscuits cg bacon kips 
Other: 
SAUCES/GRAVIES/COND~NTS 
Tomato Sauce 
Amount TIMES EATEN 
WILD BIRDS, ANIMALS OR INSECTS (hunted in rural areas or on farms) 
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MISCELLANEOUS: Please ~eDUon Iny otber foods used more than once/two weeks which we hive Dot talked about: 
FOOD DESCRIPTION Amount 
SALT USE: . 
What type of salt do you use?~ ________________ _ 
,The next few questions ar~ to find out if you use salt. where you use it and how much you use? 
.-----.------r----~----_, 
Do you add salt to food while it is being cooked? Always Sometimes Never Don't know 
1 2 J 4 
Do you add salt to your food after it has been cooked? Always Sometimes Never 
1 2 J 
Very much Like Not al all I 1 2 J Do you like salty foods eg. salted peanuts, crisps? 
Do you use any of the following: 
Name of product Amount/day 
Vitamins/vitamins & minerals 
Tonics 
Health foods 
Body building preparations 
DietarY, fibre supplement 
Other: specify 
THANK YOU FOR YOUR COOPERATION AND PATIENCE 
GOOD-BYE! 
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'-<;~ ":; ~" 
. ' ", 
Annlel~~,~e 11 
t- ..: 
~ FOOD DIARY OF VITAMIN A - RICH AND SUGAR CONTAINING FOODS 
Dear Friend, 
The purpose of this survey is to obtain information on the food that you eat, especially those that are rich in Vitamin-A and those that have sugar added. 
Please tick on appropriate column and also show the amounts that you eat for breakfast (8/F), lunch (L) and supper (S). 
Please be as honest as possible. 
We thank you for your co-operation! 
Saturda Sunday Monda 
Nl@@t!1I&tIQ9'4@@F ~mi:iijrit l@SlIMlH WWi$jMlll MHatffiWl mHWi;(iiiiNi ;m;i~MMii%jalitiM IMltllWlM @@i$i@H iWialS@H 1it!H$l!Ilt! 
whole milk 
butter 
I m~1 
I.whole milk 
live r 
carrots 
sweet 
Ipumpkin 
I apricots 
I peaches 
, 
How much sugar do ou our in/over the foil' 
soft porridge loats 
) & onion 
tea I coffee 
baked 
Icustard _____ -L 
, anLotherfood: 
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CONFERENCE PARTICIPATION & PUBLICATIONS 
1 From Lab To Land National Nutrition Conference From 15-18 August 2000, 
Durban SA 
• Oldewage-Theran. W.H; Dicks, E; Selepe, M; Grabler, C.J; van Rensburg, J; 
Hanekom, S.M. & Vorster, H.H. Demographic profile and health status of females 
aged 13-25 years old in the Vaal Triangle (poster). 
• Grabler. C.J; van Rensburg, J; Oldewage-Theran, W.H; & Selepe, M. 
Haematological iran related parameters of females aged 13-25 years old in the Vaal 
Triangle (poster). 
2 XVIth International Fibrinogen Workshop From 23-26 August 2000, Leiden The 
Netherlands 
• Grobler. C.J; Oldewage-Theron, W.H;Vorster, H.H; Veldman, D. The 
effect of fortified vitamin A on fibrinogen levels of females aged 13-
25 years in the Vaal Triangle South Africa (poster) . 
3 161h National Congress of the society of Medical Laboratory 
Technologists of South Africa from 1-4 May 2001, Eskom Conference 
Centre, Midrand Gauteng 
• Grabler. C.J; Oldewage-Theran, W.H;Vorster, H.H; Veldman, D. The 
effect of fortified vitamin A on fibrinogen levels of females aged 13-
25 years in the Vaal Triangle South Africa (oral). 
4 71h Congress of the European haematology association from 6-9 June 2002, Florence 
Italy 
• Grobler, C.J; Oldewage-Theran, W.H;Vorster, H.H; Veldman, D. The 
effect of fortified vitamin A on fibrinogen levels of females aged 13-
25 years in the Vaal Triangle South Africa (poster). 
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5 1" Africa nutritional epidemiology conference from 16-21 August 2002, 
Vanderbijlpark South Africa 
• Grobler. C.J; Oldewage-Theron, W.H;Vorster, H.H; Veldman, D. The effect of 
fortified vitamin A on fibrinogen levels of females aged 13-25 years in the Vaal 
Triangle South Africa (oral). 
6 Abstracts published in the SA Journal of Clinical Nutrition, August 
2000 
• Oldewage-Theron, W.H; Dicks, E; Selepe, M; Grobler, C.J; van Rensburg, J; 
Hanekom, S.M. & Vorster, H.H. Demographic profile and health status of females 
aged 13-25 years old in the Vaal Triangle. 
• Grobler. C.J; van Rensburg, J; Oldewage-Theron, W.H; & Selepe, M. 
Haematological iron related parameters of females aged 13-25 years old in the Vaal 
Triangle. 
7 Abstract published in The Haematology Journal- Official Journal of the European 
Haematology Association, June 2002 (volume 3 - Supplement 1: p454) 
• Grobler. C.J; Oldewage-Theron, W.H;Vorster, H.H; Veldman, D. The effect of 
fortified vitamin A on fibrinogen levels of females aged 13-25 years in the Vaal 
Triangle South Africa (oral). 
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RESEARCH PROJECT: EV ALUA TION OF THE FORTIFICATION OF SUGAR 
WITH VITAMIN A 
WHAT IS THIS PROJECT? 
The major objective of this project is to perfonn a clinical intervention trial under controlled conditions to 
examine the effect of fortified vitamin A in young, African females in order to answer the following questions: 
• Is sugar a suitable vehicle for vitamin A fortification in terms of dietary intake, bio-availability and 
consumer acceptance? 
• What effect does vitamin A fortification have on the vitamin A- and iron status of young, African females? 
• What effect does fortified vitamin A have on the fibrinogen levels? 
WHY IS THIS PROJECT IMPORTANT? 
In children three micronutrient deficiencies, namely vitamin A, iron and iodine, are considered to be a 
major health problem in developing countries. These are presently receiving high priority globally. 
Communities that are affected the most are those in si tuat ions where poverty, unemployment, civil unrest, 
war and exploitation remain endemic (SA VACG, 1995: 39; USAID, 1993: 2). Growth retardation, brain 
damage, diminished cognitive function and diminished working capacity in children and adults, as well as 
increased susceptibility to and severity of infections, and mortality are the collective result of these 
micronutrient deficiencies (SAV ACG, 1995: 39; USAlD, 1993: 2). 
PROCEDURE 
The project will take place over a period of 14 weeks. You will be requested to report to us five times 
during the 14-week period. You will be supplied with the dates to report to the Vaal Triangle Technikon to 
participate in the project. 
WHAT WILL BE MEASURED IN THE PROJECT? 
• Eating and drinking habits 
• Medical history 
• Weight, height, waist and hip circumference 
• Clinical signs of vitamin A deficiency 
• Blood sample: markers of nutritional status. PLEASE NOTE, NO HIV OR AIDS testing 
• Blood pressure 
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WHO MAY PARTICIPATE? 
Healthy AtTican females living in the Vaal Triangle who are between 13 and 25 years of age. People will 
he asked to participate and may refuse. Therefore, only volunteers will be asked to sign the informed 
consent form to participate. 
WHAT ARE THE BENEFITS FOR YOU? 
Many healthy and nutritional status indicators of yourself will be measured. You will receive feedbacjk 
during which a member of the investigation team will explain your health risk to you. You will receive 
dietary advice and will be referred to your clinic or doctor if necessary. A doctor will be supervising the 
research project and it involves a low risk. 
WHAT DO WE EXPECT OF YOU? 
• Please bring your rD, we need to know your birth date. 
• We will appreciate it if you will report fasting on the day of your participation. It means that for 10-12 
hours before your blood sample is taken, you must not eat or drink anything but pure water. 
• You will be asked to sign a form giving consent to participate in the project. 
• We will ask you a number of questions regarding your health, age, income, family, smoking and 
drinking habits. 
• Then you will receive a reference number for the project. 
• You will be weighed and measured. 
• We will take your blood pressure to determine stroke rj.sk. 
• Your temperature will be taken orally. 
• You will be questioned in detail about your eating habits. 
• You will be given sugar samples to consume for a period of6 weeks at a time. We would like you to 
use this sugar and to answer questions about the acceptability of the sugar. 
• Blood will be taken from you 5 times in a period of 14 weeks by a registered nursing sister. 
• You will receive journals to read while you wait. 
• You will receive a snack afier blood has been taken. 
If you have any questions about the project, please do not hesitate to ask anyone of the field workers at any 
time. 
Thank you for your participation. 
WHna OIdewage-Theron 
Head of Department: Food 
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